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evidence  suggesting  that  more  than  half  of  all  medicines  are  not  used  in  an 
appropriate  way.  Such  inappropriate  use  endangers  lives  and  wastes  money. 
Unfortunately, medicines use is not routinely monitored in many countries resulting 
in a dearth of  information.    Improving medicines use has not been a high priority 
globally or nationally, and many countries are not  implementing core  strategies  to 
ensure appropriate use of medicines. 
 
The  first  step  to  improving  the  current  situation  is  to measure how medicines  are 
used and  this  forms  the basis of advocacy  for change. This Fact Book describes  the 
findings from a WHO database of all the medicines use surveys and interventions to 





We hope  that  the  information presented here will  stimulate  action  to  increase  the 
rational use of medicines and that it will inform and facilitate the setting of priorities 






WHO created the database that  is the basis for all the  information contained  in this 
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SUMMARY OF KEY POINTS 
Background 






Programmes  that  include  components  to  promote  more  appropriate  use  of 
medicines. However, these efforts are often haphazard and their impacts have rarely 
been thoroughly evaluated. One reason for this may be a lack of evidence about the 
seriousness  of  the  problem  of  inappropriate  use  of  medicines  and  about  the 
effectiveness of various  small‐scale  interventions  that have been  tested  to  improve 
medicines use. 
Objective 




WHO  created  a  database  of  studies  on  the  use  of  medicines  in  primary  care  in 
developing and transitional countries. The database includes systematically extracted 
quantitative information on commonly used indicators of medicines use measured in 
these  studies  as well  as details  on  study  setting  and methodology  extracted  from 





at  the primary  care  level were  eligible  to be  included  in  the database. To  identify 
studies, we searched various sources  likely  to contain studies of  interest,  including 
the  International Network  for  the Rational Use of Drugs  (INRUD) Bibliography on 
medicines use,1 Embase, PubMed, and the archives of WHO departments concerned 
with  medicines  and  child  health;  we  also  contacted  other  agencies  involved  in 
primary care and medicines programmes for reports of medicines use studies.  To be 
included  in  the  database,  studies  had  to  report  quantitative  data  using  common 
medicines  use  indicators,  including  the  WHO/INRUD  indicators2  and  the  WHO 
IMCI  indicators.3  All  articles  identified  for  possible  entry  into  the  database  were 
reviewed by  two  authors  (KH, VI). One  author  extracted  and  entered  information 
about  the study and  the  reported data on medicines use  into  the database and  the 
other checked all entries.  
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A Microsoft Access© database was created  to  record  the extracted data.   As  far as 
possible,  the database  contains one  record per  study group  (i.e.,  a  specific  type of 
health provider practicing in a specific sector or setting); intervention studies contain 
data on  the characteristics of each of  the  individual study groups  identified by  the 
intervention  design. Data  from  the  same  study  reported  in multiple  articles were 
only entered once. Articles that reported data separately from multiple countries or 





of  2006,  with  some  additional  studies  on  the  Integrated  Management  of  Sick 
Children (IMCI) from 2007.   We converted the Access database  into SAS© to assess 
data quality and to conduct statistical analyses.   We calculated the median value of 




Studies  that  reported  the  impacts of  interventions or policies  intended  to  improve 
use  of  medicines  were  categorized  by  type  of  intervention.  We  assessed  the 
methodological quality of the research designs of these studies and limited analysis 
of  intervention  impacts  to  studies  that  met  commonly  accepted  standards  of 
adequate  study  design  (randomized  controlled  trials,  time  series  with  or  without 
comparison  series,  and  pre‐post  with  control).  Two  methods  were  used  to 
summarize the effects across studies. The first method compared the largest reported 
improvement  in a key medicines use outcome  that was  targeted by  the  individual 
authors. The  second method  calculated  a  composite  indicator  of  improvement  for 
each study by calculating the median effect across all outcome measures reported in 
the main  category of outcomes  targeted by  the authors; prescribing practices were 




records  in  the  database.  For  the  711  database  records  (representing  559  studies) 
where  the  institutional  setting  could  be  determined,  a  large  majority  (71%)  were 
undertaken in the public sector, with 29% conducted in the private sector (26% in the 
private  for‐profit  settings  and  3%  in  private  not‐for‐profit  settings).  Only  13%  of 
studies looked at medicines use in pharmacy shops and only 2% at medicines use in 





diseases  in  primary  care.  The  treatments  of  acute  respiratory  tract  infection  and 
malaria  have  not  improved  considerably  over  time;  treatment  of  diarrhoea, while 
still deficient,  shows  some  improvement. Less  than  60% of pneumonia  cases were 
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treated  with  an  appropriate  antibiotic,  and  more  than  half  of  all  cases  of  upper 
respiratory tract infection received antibiotics, most of them unnecessarily. Less than 






sector  for WHO/INRUD  prescribing  indicators  and  also  for  the  treatment  of ARI, 
diarrhoea  and  malaria.  By  contrast,  in  the  private  sector,  there  were  longer 






were  adequately  evaluated  in  81  studies.  The  evidence  base  about  intervention 
effects  has  grown  slowly  and  the  proportion  of  studies  using  acceptable  research 
designs  has  not  improved  over  time.  The  situation  is  particularly  critical  for 
interventions  to  improve  use  of  medicines  among  children,  where  a  very  small 
proportion of studies contribute to knowledge about intervention effectiveness. 
 
The  most  frequent  types  of  interventions  evaluated  have  been  educational 
programmes  for health providers, half of which were  implemented  in  conjunction 
with educational programmes  for patients or consumers. An  increasing number of 
studies have evaluated the impact of enhanced supervision, frequently accompanied 
by  routine monitoring of prescribing practice. Many  surveys have been  conducted 
during  the  implementation  of  National  Medicines  Policies,  Essential  Medicines 





outcomes  have  combined  multiple  intervention  components,  especially  those 
characterized by enhanced health worker supervision combined with provider and 
consumer  education.    Interventions  that  involve  a  group  educational  process  for 






and  transitional  countries.    Based  on  reports  published  between  1990  and  2006, 
prescribing and patient care practices did not exhibit much improvement. Since most 
studies  included  in  this  review were  conducted  in  the public  sector where use  of 
medicines is generally thought to be better than in the private sector, it is likely that 
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the  overall  situation  is  worse  than  reported.  Since  the  majority  of  health  care  is 
undertaken by  the private  sector  in many  countries,  including both  for profit  and 
non‐profit  providers  of  care,  there  is  an  urgent  need  to  conduct  more  studies  to 
measure quality of medicines use in this sector.  
 
We  found  that  only  121  of  386  interventions  were  evaluated  using  valid  study 
designs, indicating the paucity of both reported experience with interventions as well 
as  limited  evidence  about  their  effectiveness.  However,  the  limited  results  are 
generally similar  to  those from  industrialized countries. Multi‐faceted  interventions 
involving both education and managerial systems have tended to be more effective 
than  those  that  employ  one  strategy  only. Countries  need  to  extend  the  range  of 
interventions  tested,  especially  in  the  private  sector,  as  well  as  to  examine  the 
impacts  of  scaling  up  interventions  shown  to  be  effective  in  small‐scale  studies. 
Promising  approaches  include  interventions  that  have  multiple  components, 
especially  those  that  include  some  type of  enhanced  supervision or group process 
strategies.  
 
The  creation  of  the  medicines  use  database  has  allowed  the  first  systematic 
quantitative review of studies measuring medicines use indicators in developing and 
transitional  countries.  Nevertheless,  the  database  and  our  analyses  have  several 
limitations.   The database  is  limited  to  reports  of medicines use practices  thought 
important enough  to be assessed;  it  is probably not  representative of all medicines 
use problems  in developing  countries  and  it  excludes  all data  from  industrialized 
countries  where  more  is  known  about  use  of  medicines  and  intervention 
effectiveness.   While we  stratified  studies of medicines use practices by  important 
categories  (geographic  region,  country  income,  health  facility  ownership,  type  of 
prescriber),  the data were  too sparse  to conduct more elaborate statistical analyses. 
We used the median result within a group as the most representative expression of 





These  limitations  notwithstanding,  the  evidence  presented  in  this  report  about 
continuing  problems  in  use  of  medicines  is  compelling  and  should  be  used  to 
advocate for greater investment by all stakeholders in promoting appropriate use of 
medicines. 
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based  on various  ad hoc  reviews.5 Common  types  of  inappropriate medicines use 
include  polypharmacy  (the  use  of  too  many  medicines  per  patient),  overuse  of 
injections, inappropriate use of antimicrobials, failure to prescribe in accordance with 
clinical  guidelines,  and  inappropriate  self‐medication,  often with prescription‐only 
medicines.   
 
Inappropriate  use  of  medicines  is  harmful  for  patients  in  terms  of  poor  patient 
clinical outcomes and avoidable adverse drug  reactions. Overuse of antimicrobials 
exerts  pressure  to  increase  rates  of  antimicrobial  resistance.  Non‐sterile  injections 
contribute  to  the  transmission  of  hepatitis,  HIV/AIDS  and  other  blood‐borne 
diseases.6,7,8    Inappropriate  medicines  use  wastes  scarce  economic  resources  that 
could be used  for  food or other necessities. Unnecessary overuse of medicines  can 
stimulate inappropriate patient demand5 and lead to medicine stock‐outs and loss of 
patient confidence in the health system. 
1.2 Working towards rational use of medicines 
Much  has  been  done  in  the  past  20  years  to  improve  the  use  of medicines.    The 
present  definition  of  rational  use  of  medicines  was  agreed  at  the  international 
conference of experts  in Kenya  in 1985 and endorsed by a World Health Assembly 
Resolution in the following year.4  The International Network for the Rational Use of 
Drugs  (INRUD)  was  formed  in  1989  with  the  objective  of  undertaking 
multidisciplinary  intervention  research  to promote appropriate use of medicines  in 
developing  countries.9,10    INRUD  core  groups  from many  countries  in Africa  and 
Asia participated  in  the development of  the WHO/INRUD  indicators  to  investigate 
medicines  use  in  primary  care  facilities,  which  have  formed  the  basis  for 
measurement  in  many  studies  conducted  since  that  time.2  INRUD  groups  also 
spearheaded  the  testing of many  innovative  intervention studies  to  improve use of 
medicines.   
 
In 1997,  the  first  International Conference on  Improving Use of Medicines  (ICIUM) 
was held  in Chiang Mai, Thailand,  to  review global experience  in  this  field and  to 
define  future  directions  in  developing  countries.11    A  review  presented  at  the 
conference  of  all  published  studies  of  outpatient  use  of medicines  with  adequate 
study  design  revealed  that  interventions  to  improve  use  of  medicines  could  be 
successful  and  that  impacts  varied  by  intervention  type.12  Printed materials  alone 
had  little  impact  on  improving  practice.  Greater  effects  on  medicines  use  were 
associated with improved supervision, audit and feedback of practice, group process, 
Medicines use in primary care, 1990-2006 
–  2  – 
and community case management. The effects of training, the most common type of 
intervention, were  variable  and  often  unsustained,  probably  due  to  differences  in 
training  quality  and  the  absence  of  follow‐up  after  a  time‐limited  educational 
process. 
 
Based on  the evidence about problems  in medicines use and effective  interventions 
presented  at  ICIUM  1997,  WHO  developed  recommendations  for  twelve  core 
national  policies  and  structures  that  are  needed  to  promote  appropriate  use  of 
medicines (Table 1.1).5 
Table 1.1: Twelve core interventions recommended by WHO to promote more 
appropriate use of medicines 
1. A mandated multi-disciplinary national body – to coordinate medicines use policies. 
2. Evidence-based clinical guidelines – to aid prescribers on how to treat patients. 
3. Essential medicines lists based on treatment of choice – to be followed in 
procurement and distribution of medicines. 
4. Medicines and therapeutic committees – to monitor quality of care in the districts 
and hospitals under their jurisdiction. 
5. Problem-based pharmacology training in undergraduate curricula – to better equip 
future doctors in how to prescribe. 
6. Continuing in-service medical education as a licensure requirement – in order to 
ensure that prescribers remain up-to-date with new treatments. 
7. Supervision of health-care workers, audit of prescribing and feedback to prescribers 
– in order to help prescribers use medicines more appropriately. 
8. Provision of independent information (such as clinical guidelines, drug bulletins) on 
medicines – in order to make sure that prescribers have sufficient unbiased 
information on medicines. 
9. Public education about medicines to try and reduce inappropriate self-medication 
and demand for medicines and also to increase awareness about the importance of 
adherence. 
10. Avoidance of perverse financial incentives such as prescribers earning money from 
the sales of medicines which encourages over-prescription of medicines. 
11. Appropriate and enforced regulation, particularly concerning medicine promotional 
activities by the pharmaceutical industry, licensing of medicine outlets and health-
care workers, and the availability of prescription-only medicines without 
prescription. 
12. Sufficient government expenditure to ensure availability of medicines and staff. 
 
 
In 2004,  the  second  ICIUM Conference was held, again  in Chiang Mai, Thailand.13  
Review of  the  evidence presented highlighted  that  inappropriate use of medicines 





public  health  goals  through  appropriate  medicines  use.  Conference  participants 
made  three  major  recommendations  supporting  effective  national  efforts  that 
improve the use of medicines on a large scale and in a sustainable manner.  
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historical  patterns  of  medicines  use  reported  in  the  literature.    Such  data  can  be 
useful  in  advocacy,  programme  planning,  and  evaluating  medicines  policy  and 
programme  changes. These data  can  also provide  insight  into  how medicines use 
patterns  compare  across  countries  and  regions,  whether  medicines  use  improves 




are summarized  in  this document provided much of  the evidence presented  to  the 
World Health Assembly prior to adoption of resolution WHA60.16.   
1.3 Overview of this report 
This  document  summarizes  available  historical  data  on  patterns  of medicines  use 
from all relevant studies conducted prior to the end of 2006 that were reported up to 
the  end  of  data  collection  in  2006  (with  all  studies  on  integrated management  of 
childhood  illnesses  that  were  reported  in  2007).  In  Chapter  2,  we  describe  the 
structure of  the WHO medicines database and  the methods used  to summarize  the 
information included in this report. Chapters 3 to 5 provide summaries of studies on 
general  medicines  use  indicators,  while  Chapters  6  to  9  provide  summaries  of 
indicators  for  studies  of  specific  diseases  (acute  respiratory  infection,  diarrhoea, 
malaria) and medicines use problems (antimicrobial use). Chapter 10 summarizes the 
types  of  interventions  that  have  been  conducted  to  improve  medicines  use,  and 
assesses the relative impact of different types of interventions. Chapter 11 discusses 
the findings  in the  light of the  important  limitations  in collecting and analysing the 
data and recommends next steps.   
 
Annex  1  contains  tables  with  detailed  data  corresponding  to  all  of  the  figures 
presented in Chapters 3 to 9, while Annex 2 presents key descriptive indicators with 
countries classified by WHO region rather than by World Bank region which is used 
in  the  body  of  the  report. Annex  3  contains  the manual  describing  details  of  the 
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We hope  that  this summary of data from  the WHO medicines use database will be 
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2. METHODS 
2.1 Objectives of the WHO database on medicines use 






A developmental version of  the WHO database was presented at  ICIUM  in 2004.15 
Following  ICIUM  2004,  the  database  was  completed  with  studies  that  were 
conducted  up  to  the  end  of  December  2006.  Because  of  continuing  interest  in 
assessing  the  impact of various  strategies  for  integrated management of  childhood 
illnesses (IMCI), we added recent IMCI studies published in 2007 to the database.   
























Medicines use in primary care, 1990-2006 




























The database manual  in Annex 3 details  the definitions  (including  the numerators 
and  denominators)  of  each  indicator  captured  in  the  database.  It  also  gives 
instructions  on  how  to  calculate  outcome  values  for  some  indicators  in  situations 
where an article does not present data in a format that the database can accept, but 
where  there  are  sufficient  data  to  enable  calculation  of  the  indicators  used  in  the 
database. A  frequently  occurring  example  of  this  is where  data  are  presented  for 
individual health facilities but not averaged across facilities. 
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Table 2.1: List of selected medicines use indicators for the WHO database 
WHO/INRUD medicines use indicators for primary care facilities 16 
Prescribing indicators 
1. Average number of medicines prescribed per patient encounter 
2. Percentage of medicines prescribed by generic name 
3. Percentage of encounters with an antibiotic prescribed * 
4. Percentage of encounters with an injection prescribed  
5. Percentage of medicines prescribed from an EML or formulary 
Patient care indicators 
6. Average consultation time 
7. Average dispensing time 
8. Percentage of medicines actually dispensed 
9. Percentage of medicines adequately labelled 
10. Percentage of patients with knowledge of correct dose 
Facility indicators 
11. Availability of EML or formulary to practitioners 
12. Availability of clinical guidelines 
13. Percentage of key medicines available in a facility 
Complementary medicines use indicators 
14. Average medicine cost per encounter 
15. Percentage of prescriptions in accordance with clinical guidelines 
 
Disease-specific medicines use indicators 
ARI treatment indicators 
16. Percentage of pneumonia cases treated with recommended antibiotics  
17. Percentage of cases of upper respiratory tract infections treated with antibiotics 
18. Percentage of cases of acute respiratory infections treated with cough syrups  
Diarrhoea treatment indicators 
19. Percentage of cases of diarrhoea treated with antibiotics  
20. Percentage of cases of diarrhoea treated with antidiarrhoeals 
21. Percentage of cases of diarrhoea treated with oral rehydration therapy (ORT) 
Malaria treatment indicator 
22. Percentage of cases of malaria treated with recommended antimalarials  
 
Additional indicators 
23. Percentage of patients receiving medicines without prescription 
24. Percentage of cases prescribed multivitamins/tonics 
25. Percentage of injections prescribed inappropriately 
26. Percentage of patients prescribed antibiotics inappropriately 
27. Percentage of antibiotics prescribed in too low dose 






Italicized indicators are reported in the present fact book. 
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In  addition,  we  reviewed  all  studies  presented  at  the  1st  and  2nd  International 
Conferences for Improving the Use of Medicines in 1997 and 2004, respectively, and 
sought publications or  reports of  these studies  from  the authors. However, studies 
that  were  only  reported  in  abstract  form  at  the  conferences  with  no  supporting 
documentation were not included. 
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A  study was  included  in  the database  if  it was  from  a developing  or  transitional 
country and  if  it contained quantitative data describing medicines use  in a primary 
care  setting  using  standardized  indicators.  Developing/transitional  countries  were 
defined  as  all  countries  excluding  those  from Western  Europe,  the USA, Canada, 
Japan,  Australia,  and  New  Zealand.  Primary  care  settings  included  primary  care 
clinics, hospital general and paediatric non‐specialist outpatient settings, pharmacies, 
medicine  shops  and  households.  Studies  were  considered  if  they  were  published 
during  1990‐2006  (as  found  in  searches  conducted  until  December  2006)  or  IMCI 




and  other  external  library  resources.  In  addition  reports  were  retrieved  from  the 
WHO  Essential  Medicines  Documentation  Centre,  the  Departments  of  Child  and 
Adolescent Health  and Technical Cooperation  for Essential Drugs  and Traditional 
Medicine  in  WHO,  the  MSH  Rational  Pharmaceutical  Management  Project, 
individual authors, and their respective organizations.  
 
The search and retrieval strategy was  tested by comparing  the articles  found using 
the  database  search  strategy  with  selected  reference  lists  provided  by  the  Child 
Adolescent Health Department of WHO,  the Harvard Medical School Drug Policy 
Research Group, and the U.S. Centers for Disease Control in Atlanta. 
2.5 Data entry 
A main principle for design of the database and data entry was to enter individually 
identifiable  data  for  each  predefined  study  population,  as  defined  by  (1)  health 
facility  ownership  [public,  private  for‐profit,  private  not‐for‐profit];  (2)  setting 
[primary  care  centre,  hospital,  chemist,  household];  (3)  prescriber  type  [doctor, 






record  relates  to  just  one  country;  studies  reporting  data  from multiple  countries 
have been entered as separate records for each country.  Data reported in individual 
articles/reports were entered  into  the database as separate records according  to  the 
number  of  groups  studied,  as  characterized  by  unique  combinations  of  medicine 
outlet  ownership;  medicine  outlet  type;  prescriber  type;  patient  type  (outpatient, 
consumer) and time period. Data from multiple articles related to the same study or 
involving  populations  from  the  same  setting  were  assigned  a  common  study 





setting  (e.g.  health  facility  type  and  prescriber  type)  the  researchers  selected  one 
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2.6 Data cleaning 
Abstracts  of  all  identified  reports  were  screened  by  one  researcher,  the  second 
researcher  reviewed  a  random  selection  of  abstracts  to  ensure  agreement  about 
whether the full article should be retrieved. All articles retrieved were reviewed by 
two researchers, whether or not entered  into  the database. Of  the retrieved articles, 
only  those  found  to have no quantitative medicines use data were not entered  into 
the database. One researcher entered  the data and each entry was reviewed by  the 
other  researcher  for  accuracy.  In  addition,  we  exported  the  data  into  Excel 
(Microsoft® Office® Excel 2003, Microsoft Corporation, Redmond, WA) and created 
frequency distributions of key variables to assess data entry accuracy.  
2.7 Definitions, variables, and data sources 





















When  several data points were  reported  from  the  same  study  for  the  same  study 
group  in  a  given  time  period,  only  their  mean  value  was  used  in  descriptive 
analyses.  For example, if an intervention study reported different baseline values of 
an  indicator  for  a  control  group  and  two  intervention  groups,  all  of  which 
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that  have  several  similarly  defined  groups  or  studies  in  settings  that  have  been 
evaluated intensively.    
 
Furthermore,  in  studies  that  present  trends  in medicines  use  over  time,  no  study 
group was allowed  to contribute more  than one data point  in a given  time period.  





A  study  could  contribute multiple data points  for a  specific  time period  for  study 
groups that were not identical, for example, public and private sector facilities or, in 
analyses  of  differences  by  prescriber  type,  for  physician  and  non‐physician 
prescribers.  We  justify  using  multiple  data  points  in  a  time  period  from  studies 
reporting  data  in  differently  defined  study  groups  by  the  fact  that  patterns  of 
medicines use tend to differ greatly by health facility ownership and setting of care. 
2.7.1 Data sources for descriptive analyses 
We  used  the  following  data  sources  to  generate  data  points  for  the  descriptive 
analyses: data from any study that did not report on an intervention; data from the 
baseline  period  of  intervention  studies;  data  from  control  groups  of  intervention 
studies  in  all  follow‐up  periods;  and  data  from  cross‐sectional  surveys  that  were 
coded  as  post‐only  cross‐sectional  interventions  because  they  followed 
implementation of disease management or IMCI programmes. 
2.7.2 Data sources for intervention analyses 
All  studies  describing  an  intervention were  included  in  the  overall  description  of 
intervention studies.   Only data from  intervention studies with valid study designs 






2.8 Data analysis  
We  exported  the Access database  into an analytic  relational database  in SAS  (SAS 
Institute,  Inc,  Cary,  NC).    We  conducted  descriptive  analyses  of  key  descriptive 
study  variables.    Values  of  each  medicines  use  indicator  from  each  study  were 
summarized by calculating medians and 25th and 75th percentiles across studies that 
reported  that  indicator,  overall  and  for  studies  that  reported  on medicines  use  in 
specific provider, facility and patient groups.  
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We conducted sensitivity analyses to determine the impact of excluding data points 
from  the  analyses  of  descriptive  studies  of  cross‐sectional  studies  of  disease 
management  and  IMCI  programmes,  as  some  might  argue  that  these  describe 
patterns  of  medicines  use  after  an  intervention  has  occurred  (although  in  these 
studies,  the  interventions  cannot  be  clearly  defined).    Exclusion  of  cross‐sectional 
studies  of  disease  management  and  IMCI  programmes  (n=89)  did  not  materially 
change  the  results  and  the  analyses  presented  in  this  Fact  Book  includes  these 
studies.   













the  indicators depicted  in  the graphs, and additional data elements  (the number of 
studies used in calculating the median, as well as the 25th and 75th percentiles of the 
distribution). 
2.8.2 Intervention impact analysis 
Additional  analyses  were  conducted  to  evaluate  the  impact  of  interventions.  For 
these analyses only studies using adequate methodology were included. Acceptable 
study designs consisted of randomized controlled trials, interrupted time series with 
or  without  comparison  group(s),  and  pre‐post  studies  with  one  or  more  control 
groups. For the time series design, a minimum of four time points were required, one 
to  summarize  the  pre‐intervention  value  and  three  to  capture  post‐intervention 
values.   Studies using a post‐only with  control design or pre‐post with no  control 
study design were excluded from the intervention impact analyses. 
 
The  rates of prescribing practices were  the primary outcomes of  interest. Mortality 
rates  are  also  used  as  the  primary  outcomes  of  interest  for  community  case 
management  interventions.    A  major  aim  of  the  analysis  was  to  draw  basic 
conclusions about both the quality of research evidence and the relative effectiveness 
of  different  intervention  strategies  in  improving  prescribing.  We  followed  the 
method developed by Ross‐Degnan and colleagues in their review of improving use 
of  medicines  for  the  first  International  Conference  for  Improving  the  Use  of 
Medicines  (Ross‐Degnan  et  al.  1997,  unpublished  and  WHO  199722).  The  method 
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summarizes relative effect sizes of all interventions, in the face of relative paucity of 
studies  and  variation  in  environments,  strategies,  target  audiences,  practices  and 
outcomes used. 
 
To evaluate each  intervention,  focus was given  to  the outcome measures  identified 
by the authors as the principal targets for their interventions, as well as to the single 
measure  with  largest  positive  change  in  terms  of  better  medicines  use,  e.g.  a 
reduction  in  antibiotic  use  for  acute  diarrhoea  or  viral  upper  respiratory  tract 
infection or an increase in compliance with standard treatment guidelines. For most 
studies, outcome measures  included  indicators of  appropriate prescribing,  such  as 
antibiotic  use,  injection  use  or  adherence  to  clinical  guidelines;  some  studies  also 
included  patient  care  indicators,  such  as  consultation  time  or  patient  knowledge 
about how  to use dispensed medications.   A number  of  studies were designed  to 





For  each  of  the  outcome  measures  identified  as  relevant,  an  effect  size  was 
calculated.  If  the  outcome  was  measured  as  a  percentage,  the  effect  size  was 
computed  as  the  relative  gain  in  the  intervention  group,  i.e.  the  percentage‐point 
improvement, of  the  intervention group over  the percentage point  improvement  in 
the  comparison group. For  time‐series with no  control,  the  effect  size was  the net 
difference  between  the  last  post‐intervention  value  reported  and  pre‐intervention 
value. If the outcome was measured as a number (e.g. average number of medicines 
per  patient),  the  changes  (from  pre‐intervention  to  post)  were  converted  to 













interventions.  Secondly,  since  one  single  indicator may  not  adequately  reflect  the 
actual  overall  impact  of  an  intervention,  a  composite  indicator was  calculated  by 
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The  present  report  constitutes  a  practical  approach  to  assessing medicines  use  in 
primary  care  by  compiling  information  from  existing  reports.  However,  both  the 
collection of data entered  in  the database and  the analytic approaches  to analysing 
these data have notable limitations.   
2.9.1 Limitations of the data collection 
The  WHO  database  of  reports  on  medicines  use  is  not  entirely  representative  of 
medicines use in developing and transitional countries.  While much effort was made 
to  find  all  existing  published  and  unpublished  reports  on  medicines  use  in 
developing and transitional countries during the past 25 years, we have undoubtedly 
not found all.  The database is likely lacking many unpublished studies conducted at 
country  level as well as many  interventions carried out and evaluated  in countries, 
such as training, formularies, bulletins and supervision, which were not evaluated or 
reported.  Even if we had retrieved all evaluations of medicines use ever conducted, 
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A great effort was made to abstract data from articles as accurately as possible and to 
give  a  true  description  of  all  studies  entered  into  the  database.  For  every  open 
question  an  attempt  was  made  to  contact  the  study  authors.  However,  only  a 
minority of authors responded.  
2.9.2 Limitations of the data analysis: Description of medicines use 
Our  analyses  are  descriptive  and  do  not  take  variability  of  data  or  potential 
confounders properly into account.  Medicines use indicators differed over time and 
by  sector,  facility  and prescriber  characteristics.   To  avoid modelling mean  (rather 
than median) indicator values (which are unduly influenced by outliers), we did not 
conduct multivariate  regression  analyses.   We  stratified by key  sector,  facility  and 
prescriber  characteristics,  but did  not  simultaneously  control  for differences  in  all 
characteristics.   Therefore  apparent differences  in performance between groups on 
one or more indicators may be due to multiple factors. 
 
We did  not weight  study  results  by  study  size  to  avoid  undue  influence  of  large 







from  any  graphic  presentations.    However,  all  summary  data  are  reported  in 
Annex 1. 
2.9.3 Limitations of the data analysis: Evaluation of interventions 
A major  limitation  to  the  evaluation  of  intervention  studies  is  their  heterogeneity 
with  respect  to  the  nature  of  the  interventions  studied,  the  settings  of  the 
interventions, and their specific targets. In the light of these uncertainties, effect size 
comparisons  are  tenuous  and  should  be  used  as  a  basis  for  further  careful 
experimental comparisons of intervention methods in specific settings. 
Medicines use in primary care, 1990-2006 
–  16  – 
 
  Description of studies 
–  17  – 
3. DESCRIPTION OF STUDIES 
3.1 Results of search in published and unpublished literature 
Abstracts  and  executive  summaries  were  screened  from  7824  articles  from  the 
INRUD bibliography  (16 December 2007) and all  the  reports  in  the documentation 
centres of the Departments of Essential Medicines and Child and Adolescent Health 
in  WHO.  In  addition,  various  discrete  searches  were  undertaken  as  described  in 
section 2.4. Of all the complete articles retrieved, 404 articles were found to have no 
relevant data that could be extracted. For the period 1990‐2006 (as of December 2006), 
679 studies  from 97 countries were  identified and entered  into  the database as 856 
database records. A  third of  the studies  investigated medicines use  in children  less 
than  5  years  old,  and  312  of  679  studies  (46%)  were  done  in  association  with 
evaluating an intervention (including those of both good and poor study designs for 
evaluation).  
3.2 Cross-sectional studies of medicines use and patient care 
Cross‐sectional  studies of medicines use  and patient  care  identified by  the  criteria 
described in Section 2.4 were organized by periods of data collection. Because of the 
small number of  earlier  studies,  the  first  10 years were grouped  together  into one 
period, with subsequent years grouped into three‐year periods.  
 
Studies were also organized by geographic origin.  India had  the  largest number of 
studies with 60, followed by Nepal with 35, the United Republic of Tanzania with 24, 
and Uganda with 23 studies. We classified studies geographically  in two ways, one 
using  WHO  regions,  the  other  using  World  Bank  regions.  Studies  were  also 
organized by the economic level of countries where they were conducted, using the 
World Bank classification   based on 2006 Gross National  Income  (GNI) per  capita. 
Because of the small number of studies coming from upper‐middle and high income 
countries  (given  the  focus of  the  review on developing and  transitional  countries), 
data from these two economic regions were analysed as one group. 
 
Studies were divided  into  four  categories defined by  the ownership of  the health‐





did not  belong  to  any  of  the  above  categories,  either  because  they  evaluated  self‐
medication  (patients’  interviews  in health‐care  facilities),  included  several  types of 
health‐care  facilities,  or  did  not  include  a  health‐care  facility  description,  were 
classified  as  ‘not  applicable,  self‐medication’.  More  than  half  the  studies  (66%) 
focused on the public health sector, 14% on the private for‐profit sector and 1.5% on 
the  non‐profit  sector, which  includes missions  and  other  charitable  organizations. 
The  remaining  studies  were  classified  as  ‘unspecified’  (unknown)  or  ‘not 
applicable/self‐medication’. 
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• The entire database consisted of 679 studies of medicines use covering 25 years of data 
collection up to December 2006.  
• The first 10-year period from 1982 to 1991 contributed 16% of the compiled data.   
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Figure 3.2 shows the number and percentage of studies by geographic origin, using 
the  World  Bank  regional  classification  to  group  countries.  Because  of  the  small 
number of studies coming from countries in the Europe and Central Asia region and 
in  the Middle  East  and North Africa  region,  data  from  these  two  regions will  be 
presented as one group in the remaining graphs of the report.   
 














Latin America and Caribbean
Eastern Europe and Central
Asia
Middle East and North Africa






• The largest number of studies came from the WB Africa region, representing over 40% of the 
studies.  
• Over a third of studies originated in the WB South Asia (21%) and East Asia/ Pacific (15%) 
regions. 
• About one in ten studies came from the WB Latin America/Caribbean region.  
• The remaining studies came from the Middle East/ North Africa and the Europe/Central Asia 





studies  were  undertaken  in  the  African  and  South  East  Asian  regions.  Very  few 
studies have been conducted  in  the European region.   Several studies are  included 
from  the  Eastern  European  region  which  covers  central  Asia  and  the  newly 
independent states; Western Europe (part of the WHO EURO region) was excluded 
since the database focused on developing and transitional countries. 
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• The largest number of studies of medicines use came from the Africa WHO region (AFRO), 
representing over 40% of the studies in the database. 
• A third of the studies originated from the WHO South East Asia (SEARO) and Western Pacific 
(WPRO) regions. 
• About one in 10 studies came from the WHO Americas region (AMRO/PAHO). 
• The remaining studies came from the WHO Eastern Mediterranean (EMRO) and Eastern 




using World Bank data on 2006 Gross National  Income  (GNI) per  capita  to group 
countries.  Because  of  the  small  number  of  studies  from  upper‐middle  and  high 
income countries, these two economic regions are presented as one group. 
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Upper-Middle & High Income
 
Key Points: 
• Over 60% of studies of medicines use originated from low income countries. 
• Almost nine in ten identified studies of medicines use were conducted in low income or lower-
middle income countries 
• The remaining studies originated in upper-middle and high income countries, with the largest 
contingent coming from Mexico, South Africa, Brazil, and Malaysia. 
 
 
Figure  3.5  shows  the  number  and  percentage  of  studies  of  medicines  use  by 
prescriber type.   


















• A subset of 518 studies of medicines use, representing 76% of the studies, identified the 
prescriber to be a medical doctor, paramedical health worker, or a nurse. 
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Figure 3.6 presents studies of medicines use by type of ownership of the health‐care 
facilities investigated.  



















• The majority of studies of medicines use investigated health-care facilities from the public 
sector. 
• About one in seven studies reported medicines use in the private for-profit sector. 
• Very few studies examined the private not-for-profit sector. 
 
 
Figure  3.7  shows  the  number  and  percentage  of  studies  of  medicines  use  within 
different types of health‐care facility.   
























• Overall, 80% of studies in the database investigated medicines use in hospitals, primary care 
facilities or health centres (PHCs), with over half of these evaluating practices in primary care 
facilities. 
• One in five studies examined use of medicines in chemists, other medicine retail outlets, or in 
households. 
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(32%),  acute  respiratory  tract  infections  (30%),  and  malaria  (15%),  or  sexually 
transmitted  diseases  (4%).    Many  of  these  studies  were  associated  with  various 
national  and  international  vertical  control  programmes  to  reduce  childhood 
mortality  and, more  recently,  to  the  implementation of  Integrated Management of 
Childhood Illnesses (IMCI) which represents 8% of studies in the database.23 Results 
related  to  the  treatment of  specific diseases are presented  in Sections 6  to 8 of  the 
report.  
 
Medicines use in primary care, 1990-2006 
–  24  – 
 
  WHO/INRUD prescribing indicators 
–  25  – 
4. WHO/INRUD PRESCRIBING INDICATORS  
WHO/INRUD  indicators can be used  to explore patterns of prescribing  in primary 
care  in developing and  transitional  countries. This  section examines WHO/INRUD 
prescribing indicators extracted from studies of medicines use as described in Table 
2.1,  regardless  of  patients’  age  or disease. Results  are  presented  in  relation  to  the 
chronological  period  of  data  collection,  geographic  origin  of  studies,  health‐care 
facility ownership, and type of prescriber for the following indicators: percentage of 
medicines  from  EML/formulary,  percentage  of  medicines  prescribed  by  generic 
name,  percentage  of  patients with  an  antibiotic  prescribed,  percentage  of  patients 
with  an  injection  prescribed,  percentage  of  patients  treated  according  to  clinical 
guidelines, and average number of medicines per patient. 
4.1 Medicines use over time  
Figure  4.1  shows  results  for  WHO/INRUD  prescribing  indicators  in  studies  of 
medicines  use  over  time.  Observed  trends  provide  a  meaningful  indication  of 
changes  in prescribing patterns over  time. However, prescribing  indicators  cannot 
differentiate  prescribers’  practices  from  patients  needs,  and  extrapolating  reasons 
behind observed  trends  is not possible because of  the multiple  factors  influencing 
prescribing. 
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% Medicines from EML or Formulary % Medicines Prescribed by Generic Name
% Patients with an Antibiotic Prescribed % Patients with Injection Prescribed
% Treated According to Clinical Guidelines Average Number of Medicines per Patient  
 
Key Points: 
• Results from studies of medicines use suggest that prescribing patterns have not improved 
consistently overtime. 
• The percentage of prescribed medicines present on an EML/formulary seems to have increased 
in 25 years. This encouraging trend has been progressive, and may reflect an increased 
availability of EML/formularies and/or better awareness of their existence.   
• The percentage of medicines prescribed by generic name increased steadily to reach over 70% 
in the 2004-2006 period of data collection. This trend may be related to an increased 
availability of generics and implementation of generic prescribing and dispensing policies.   
• In contrast to these positive trends, the percentage of patients treated according to clinical 
guidelines remained at substandard levels, below 50% at every period of data collection from 
1992 on. 
• The percentage of patients with an antibiotic prescribed remained stable over time at between 
40% and 50%. This indicator did not differentiate between appropriate and inappropriate 
antibiotic prescribing.  
• The percentage of patients with an injection prescribed and the average number of medicines 
per patient showed no apparent trends over the years. 
4.2 Medicines use by region  
Figure  4.2  presents  overall  results  of  the  WHO/INRUD  prescribing  indicators  in 
studies  of medicines  use  by World  Bank  region.  Because  of  the  small  number  of 
studies  from  the Middle East/North Africa and Europe/Central Asia  regions,  these 
were grouped under one Middle East and Central Asia region.  
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Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results from studies of medicines use provide a mixed picture of prescribing patterns across 
different geographic regions over the entire period of data collection.   
• Studies from Africa pointed towards positive characteristics in this region, with the highest 
percentage of medicines prescribed from an EML/formulary, and the highest percentage of 
patients treated according to clinical guidelines. However, they also showed the highest 
percentage of patients with an injection prescribed.  
• Studies from Latin America had the highest percentage of medicines prescribed by generic 
name, while studies from Middle East and Central Asia had the lowest.  
• The percentage of reported patients with an antibiotic prescribed was similar across regions. 
• Across regions, studies reported up to 3 medicines prescribed per patient.  
• The percentage of compliance with clinical guidelines was below 50% in all regions. 
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Figure  4.3  presents  overall  results  of  the  WHO/INRUD  prescribing  indicators  in 
studies of medicines use by World Bank income level of countries where they were 
conducted.  




































































Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• Results from studies of medicines use may indicate disparities in prescribing patterns across 
regions of different economic level.  
• Studies from low income settings suggest a higher percentage of medicines prescribed from 
EML/formularies and by generic name in these countries. Nevertheless, they also report the 
highest percentages of patients treated with an antibiotic and with an injection.  
• The percentage of patients treated according to clinical guidelines was below 50% regardless 
of income level of the country where studies were conducted. 
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Figure 4.4  shows  results of  the percentage of patients  treated according  to  clinical 
guidelines in the identified studies of medicines use, by chronological periods of data 
collection  and  by  World  Bank  region.  Adherence  to  clinical  guidelines  refers  to 
adherence  to prescribing guidelines as  it  relates  to  the  choice of medicine, dosage, 
and  duration.  Chronological  periods  have  been  grouped  into  three  to  highlight 
overall trends.  





















Sub-Saharan Africa Latin America and Caribbean




• Overall, results from studies of medicines use show that only half of the patients or less were 
prescribed medicines according to clinical guidelines during the most recent period of data 
collection, regardless of the geographic origin of studies.   
• This percentage increased slightly in studies from Middle East & Central Asia and East Asia & 
Pacific, suggesting some degree of improvement in adherence to prescribing guidelines 
between the 1982-1994 and 2001-2006 periods in these regions. Overall compliance with 
guidelines remained low. 
• The sample of studies between 2001 and 2006 with data on adherence to prescribing clinical 
guidelines may be too small in all regions but Africa to interpret results of this period with 
confidence.  
4.3 Medicines use by type of prescriber  
Figure 4.5 presents overall results of the WHO/INRUD prescribing indicators by type 
of  prescriber,  regardless  of  the  chronological  period  of  data  collection,  region,  or 
ownership of health‐care facility. 
Medicines use in primary care, 1990-2006 
–  30  – 




































































MD Paramedic or Nurse Pharmacy Staff, Other, or Unspecified  
 
Key Points: 
• Results from studies of medicines use suggest that prescribing patterns were substandard 
regardless of the type of prescriber. 
• Paramedical health-care workers/nurses prescribed more generic medicines and more 
medicines from EML/formularies than medical doctors. 
• Results did not uncover other important differences between the prescribing of medical doctors 
and that of paramedical health-care workers/nurses. 
4.4 Medicines use by health-care facility ownership  
Figure  4.6  presents  overall  results  of  the  WHO/INRUD  prescribing  indicators  by 
ownership of health‐care facility, regardless of chronological period of data collection 
or  region.    A  key  policy  issue  in  many  countries  is  whether  prescribing  is  more 
appropriate  in  the  public  or  private  sector.    Since  many  private  sector  studies 
measure  the  practices  of  unqualified  pharmacists  and  shop  attendants  (see 
Figure 4.5),  the comparison between public and private sector practices may not be 
valid.   Therefore  the  following comparison  is based only on studies measuring  the 
prescribing of physicians, nurses, or paramedics. 
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Figure 4.6: WHO/INRUD prescribing indicators by health facility ownership (prescribing 




































































Public Private, for profit Private, not for profit  
 
Key Points: 
• Overall, results suggest better prescribing patterns in public health-care facilities than in 
private for-profit facilities. 
• Generics and medicines prescribed from an EML/formulary were much higher in studies in both 
the public and private not-for-profit sectors than in the private for-profit sector. 
• The percentage of patients with an antibiotic prescribed was equivalently high in all sectors, at 
nearly half of all patients; about 20% of patients received an injection in the public and private 
for-profit sectors, but this percentage was much higher in studies from the private not-for-
profit sectors.  
• The percentages of patients treated according to clinical guidelines were low in both the public 
and private for-profit sectors, although somewhat higher in the public sector. 
• Fewer medicines were prescribed on average in the public sector (2.4 per patient) than in 
either of the private sectors (3.0 per patient).  
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ownership,  and  type  of  prescriber.  The  following  indicators  of  patient  care  were 
evaluated:  percentage  of  prescribed  medicines  actually  dispensed,  percentage  of 
medicines  adequately  labelled,  percentage  of  patients  given  dosage  instructions, 
percentage of patients with knowledge of correct dose, average consultation time in 
minutes, and average dispensing time in minutes. The following health‐care facility 
indicators  were  evaluated:  percentage  of  key  medicines  available  in  facility, 
availability of clinical guidelines, and availability of EML/formulary.    
5.1 Patient care indicators 
Figure 5.1 displays results of the WHO/INRUD patient care  indicators  in studies of 
medicines  use  by  chronological  periods  of  data  collection,  regardless  of  region, 
ownership of health‐care facility, or type of prescriber.  
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% Prescribed Medicines Dispensed % Medicines Adequately Labeled
% Patients Given Dosage Instructions % Patients with Knowledge of Correct Dose
Average Consultation Time (minutes) Average Dispensing Time (minutes)  
 
Key Points: 
• Results from studies of medicines use suggest some improvement over time in many aspects 
of patient care related to the use of medicines. Most positive trends remain even after taking 
into account the fact that some of the low baseline values may be due to a very small 1982-
1991 sample of studies collecting data on these indicators.  
• The percentage of reported prescribed medicines that are actually dispensed increased by 10% 
over time to reach 92% in the most recent data collection period.  
• The average consultation time showed improvement over time and the percentage of reported 
patients who were given dosage instructions increased slightly. 
• The percentage of reported medicines adequately labelled increased noticeably over time.  
• The percentage of patients with knowledge of the correct dose also showed a positive trend. 
However, over 25% of patients did not know which dose of medicine to take in the most recent 
studies. 
• The average dispensing time, which includes preparation of a prescription and interaction 
between patient and dispenser, started low and remained at just over one minute in the most 
recent data collection period. 
 
 
Figure  5.2  displays  results  of  the  WHO/INRUD  patient  care  indicators  in  the 
identified studies of medicines use by region, regardless of chronological periods of 
data  collection, ownership of health‐care  facility, or  type of prescriber.   Because of 
the small number of studies from the Middle East/North Africa and Europe/Central 
Asia regions, these were grouped into one Middle East and Central Asia region. 
 WHO/INRUD patient care and facility indicators 
–  35  – 






























































Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results from studies of medicines use suggest that overall trends in patient care indicators 
were similar across different regions of the world for the 1982-2006 period of data collection.  
• Low average dispensing times, insufficient instructions to patients, and lack of patient 
knowledge about how to take their medicines were problems in all regions of the world. 
• Studies from East Asia and Pacific reported the highest percentage of prescribed medicines 
actually dispensed, the highest percentage of patients given dosage instructions,  and the 
highest percentage of patients with knowledge of the correct dose.   
• Studies from Latin America reported highest average consultation time.  
• Studies from Middle East and Central Asia reported the highest rate of adequate labelling while 
South Asia studies reported almost no medicines adequately labelled. 
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Figure  5.3  presents  overall  results  of  the  patient  care  indicators  in  studies  of 
medicines use by World Bank income level of countries where they were conducted.  






























































Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• Results from studies of medicines use suggest variable differences in patient care indicators 
across regions of different economic level.  
• Studies from low income settings have the lowest percentage of medicines adequately labelled, 
the lowest percentage of patients given dosage instructions, the lowest percentage of patients 
with knowledge of correct dose, and the lowest percentage of prescribed medicines actually 
dispensed.  
• Studies from low-middle income countries have the highest percentage of medicines 
adequately labelled, highest percentage of patients with knowledge of correct dose, and 




of medicines  use  by  ownership  of  health‐care  facility,  regardless  of  chronological 
periods  of  data  collection,  region,  or  type  of  prescribers.  For  these  indicators,  the 
sample size of private health‐care  facilities was consistently below 15, which  limits 
the  interpretation  of  differences  between  the  private  and  public  sectors.  No  data 
points  were  available  to  calculate  the  percentage  of  patients  given  dosage 
instructions in studies conducted in private not‐for‐profit facilities. 
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Public Private, for profit Private, not for profit  
 
Key Points: 
• Results from studies of medicines use suggest that overall patient care indicators were better 
in studies from private sectors. However, the small sample size of studies in both private for-
profit and not-for-profit facilities with data on patient care indicators limits the reliability of this 
finding.    
• The sample size of studies in the public sector was large, and results there suggest inadequate 
patient care indicators of medicines use.   
• In studies of public health-care facilities, only half of the patients received dosage instructions, 
and more than a third of patients did not know which dose of prescribed medicine to take.  
• Average consultation time in public health-care facility studies was only four minutes and 
average dispensing time was just over one minute.  
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% Key Medicines Available in Facility Availability of Clinical Guidelines
Availability of EML or Formulary  
 
Key Points: 
• Results from studies of medicines use suggest a lack of improvement in key health-care facility 
indicators over time.  
• Reported availability of an EML or formulary to prescribers was highly variable across the time 
periods, ranging from about 40% to about 80% without a consistent pattern. 
• Availability of clinical guidelines to prescribers did not seem to improve over time. In 2004-
2006, only half of health-care facilities were reported to have clinical guidelines available 
during indicator surveys.   
• The percentage of key medicines available in health-care facilities fluctuated between 70% and 
80%. Overall, about two out of ten key medicines were not available in the health-care 
facilities investigated.  
 
 
Figure  5.6  displays  results  of  WHO/INRUD  health‐care  facility  indicators  in  the 
studies of medicines use by World Bank region, regardless of chronological periods 
of data collection or ownership of health‐care facility. Because of the small number of 
studies  from  the Middle East/North Africa and Europe/Central Asia  regions,  these 
were grouped into one Middle East and Central Asia region.     
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Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results from studies of medicines use suggest that overall trends in patient care and health-
care facility indicators varied across different regions for the 1982-2006 period of data 
collection.  
• Studies from South Asia suggest that clinical guidelines and EML/formularies were rarely 
accessible to prescribers in this region; however, the small sample size may limit the 
significance of this finding.  
• In studies conducted in other regions of the world, the availability of clinical guidelines and 
EML/formularies was higher. Still clinical guidelines were not accessible to prescribers in half of 
the health-care facilities in studies from Africa and Latin America.  
• The percentage of key medicines available in health-care facilities was lowest in studies from 
Latin America where three out of ten key medicines were not available in health-care facilities. 
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Figure 5.7 presents overall results of  the health‐care  facility  indicators  in studies of 
medicines use by World Bank income level of countries where they were conducted.  


























Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• Results from studies of medicines use suggest differences in availability of clinical guidelines 
across regions of different economic level.  
• Studies from low income settings have the lowest percentages of clinical guidelines and 
EML/formularies available to prescribers. These percentages increased with country income 
level. 
• The percentage of key medicines available in the health-care facility seemed similar across 
regions of different economic level. 
 
 
Figure  5.8  displays  results  of  WHO/INRUD  health‐care  facility  indicators  in  the 
studies  of  medicines  use  by  ownership  of  health‐care  facility,  regardless  of 
chronological periods of data collection or region. Too few data points were available 
to  calculate  two of  the  three  indicators  in  the private not‐for‐profit  sector and one 
indicator in the private for‐profit sector. 
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Public Private, for profit Private, not for profit  
 
Key Points: 
• Two out of ten key medicines were not available in public and private for-profit health-care 
facilities. The percentage of key medicines available in private not-for-profit health-care 
facilities was slightly higher.   
• In about 40% of public health-care facilities, prescribers did not have access to clinical 
guidelines. However, the situation appeared to be much worse in the private for-profit sector.  
• In half of public health-care facilities, EML/formularies were not available to prescribers. 
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6. TREATMENT OF ACUTE RESPIRATORY TRACT 
INFECTIONS 
This  section  focuses on  results about  treatment of acute  respiratory  tract  infections 
(ARI)  from  studies  conducted  between  1982  and  2006. ARI  prescribing  indicators 





















6.1 Patterns in treatment of ARI over time 
Figure  6.1  presents  ARI  prescribing  indicators  for  patients  of  all  ages  over  the 
chronological periods of data collection. 
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% Cases of URTI  Treated with Antibiotics
% Pneumonia Cases Treated with Recommended Antibiotics
% Treated According to Clinical Guidelines
% ARI Cases Treated with Cough Syrups  
 
Key Points: 
• Results from studies reporting medicines use in ARI suggest that ARI prescribing patterns may 
have deteriorated over time. 
• The percentage of reported viral URTI treated with antibiotics increased over time to 71% 
during the 2004-2006 period. 
• Over 20% of reported pneumonia cases were not treated with appropriate antibiotics during 
that period.  
• Reported compliance with ARI standard treatment guidelines appeared to decrease overtime. 
During the most recent period of data collection, the percentage of reported patients treated 
according to ARI clinical guidelines was below 40%. 
• There may have been a decrease in the use of cough syrups over time, although small sample 




under 5 years old.   Figure 6.2 presents ARI prescribing  indicators over  time  in  the 
subset of studies focusing on children less than 5 years old with ARI. 
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Figure 6.2: ARI treatment indicators over time, including only studies of medicines use 
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Key Points: 
• Results from studies reporting medicines use suggest that treatment of ARI in children less 
than 5 years old did not improve over 25 years of data collection. 
• The percentage of children under 5 years old with reported viral URTI who were treated with 
antibiotics almost doubled over 25 years to reach over 70% in 2004-2006. 
• During 2004-2006, over 30% of children less than 5 years old with reported pneumonia were 
not treated with appropriate antibiotics. 
• The percentage of children under 5 years old with ARI who were treated according to clinical 
guidelines did not improve overtime, and was below 40% during the 2004-2006 period of data 
collection.  
• The small sample size of studies with data on cough syrup use may explain the observed 
fluctuations in percentage of ARI cases treated with cough syrups. 
6.2 Patterns in treatment of ARI by region, facility ownership, 
and prescriber type 
Figure 6.3 presents overall results of ARI prescribing  indicators averaged by World 
Bank  region. Studies were  classified according  to where  they were  conducted  into 
categories of World Bank regions. To ensure a reasonable sample size in each group, 
studies  from  the Middle East, North Africa, Europe and Central Asia  region were 
grouped into one Middle East and Central Asia region.  
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Figure 6.3: ARI treatment indicators including all studies of medicines use in ARI, by 
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Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results from studies of medicines use suggest inadequate ARI prescribing patterns in every 
geographic region of the world.   
• Everywhere, a large percentage of viral URTI study cases were treated with antibiotics, over 
70% in Africa. 
• In every region at least 25% of reported pneumonia cases were treated with inappropriate 
antibiotics.   
• The percentage of ARI cases treated according to clinical guidelines was reported below 50% in 
studies from all regions, except from Latin America.  
• Results suggest that the use of cough syrups was more prevalent in the Middle East and 
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Figure 6.4: ARI treatment indicators including all studies of medicines use in ARI, by 































Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• Results from studies of medicines use suggest similarities and differences in prescribing 
patterns for ARI across income regions.   
• Everywhere, a large percentage of viral URTI study cases were treated with antibiotics. 
• Studies from low income countries had the lowest percentage of pneumonia cases treated with 
recommended antibiotics, and the lowest percentage of patients treated according to clinical 
guidelines.  
• The percentage of ARI cases treated with cough syrups was lowest in low income countries. 
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Figure 6.5 presents overall results of ARI treatment indicators by type of prescriber.  
Figure 6.5: ARI treatment indicators including all studies of medicines use in ARI, by 
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• Results from studies of medicines use in ARI suggest unsatisfactory prescribing patterns by all 
cadres of health worker.  
• Medical doctors prescribed antibiotics in reported cases of viral URTI more often than 
paramedical health workers/nurses. 
• Almost 30% of reported cases of pneumonia treated by medical doctors were not prescribed 
appropriate antibiotics. This percentage was higher for paramedical health workers/nurses 
(close to 40%) and highest for the third category, which included pharmacy staff, lay persons, 
or unspecified prescribers.  
• Only about 40% of prescribers were reported to treat ARI according to clinical guidelines, with 




Figure  6.6  presents  overall  results  of  ARI  treatment  indicators  averaged  by 
ownership  of  health‐care  facility. No data were  available  for  two  of  the  four ARI 
treatment  indicators  in  studies  conducted  in  the  private  not‐for‐profit  sector  and 
there were  fewer  than  four  studies  reporting  the  other  two  indicators,  thus  these 
results are not displayed  in  the  figure.   To enhance comparability between sectors, 
the  figure  includes  data  only  from  studies  assessing  prescribing  by  physicians, 
nurses, or paramedics.  
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Figure 6.6: ARI treatment indicators including all studies of medicines use in ARI, by 
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Public Private, for profit Private, not for profit  
 
Key Points: 
• Overall quality of care for ARI was poor in both the public and private sectors.  
• The percentage of cases of viral URTI treated with antibiotics was substantially higher in 
private for-profit facilities than in public facilities. 
• Only about two-thirds of reported pneumonia cases treated in both public health-care and 
private for-profit facilities received appropriate antibiotics.  
• The percentage of ARI patients treated according to clinical guidelines was about 40% in public 
health-care facilities; there were too few studies in the private sectors to evaluate this 
indicator.  
• Over 40% of cases in both the public and private for-profit sectors were treated with cough 
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Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• The availability of key medicines to treat acute respiratory tract infection was below 80% in 
studies in all regions (too few studies were reported in Middle East and Central Asia and in East 
Asia and Pacific to summarize practice). 
• Availability of medicines was particularly low in health facilities in Latin America and the 
Caribbean (60%) and South Asia (70%). 
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7. TREATMENT OF ACUTE DIARRHOEA 
This section focuses on studies of medicines use that reported results about treatment 
of  acute  diarrhoea  from  data  collected  between  1982  and  2006.  The  term  acute 
diarrhoea  included all  types of acute diarrhoea,  including bloody diarrhoea. Acute 
diarrhoea prescribing  indicators were  extracted  from  this  subgroup of  studies and 






















7.1 Patterns in treatment of acute diarrhoea over time  
Figure 7.1 displays acute diarrhoea treatment indicators for patients of all ages over 
the chronological periods of data collection.  
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Figure 7.1: Diarrhoea treatment indicators over time, including all studies of medicines 
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Key Points: 
• Results from studies reporting medicines use suggest that patterns of acute diarrhoea 
prescribing have not improved consistently over time. 
• Results suggest encouraging progress in ORT prescribing. The percentage of reported 
diarrhoea cases treated with ORT increased over time, to over 70% in 2004-2006. 
• The reported use of antibiotics for acute diarrhoea fluctuated without distinct trends, while the 
use of antidiarrhoeals markedly decreased over time.  
• Reported compliance with standard treatment guidelines for acute diarrhoea appeared to 
remain low over time. During the most recent period of data collection, the percentage of 
patients with acute diarrhoea who were treated according to clinical guidelines was still 
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Figure 7.2: Diarrhoea treatment indicators over time, including only studies of medicines 





















% Diarrhoea Cases Treated with Antibiotics % Diarrhoea Cases Treated with Antidiarrhoeals
% Diarrhoea Cases Treated with ORT % Treated According to Clinical Guidelines  
 
Key Points: 
• Results suggest that prescribing patterns for children less than 5 years old diagnosed with 
acute diarrhoea have not consistently improved over time. 
• The reported use of ORT for acute diarrhoea increased over time, while the use of antibiotics 
appeared to decrease in the mid-1990’s but has risen again since then.     
• Results suggest a slight positive trend with regards to antidiarrhoeal use. The percentage of 
reported diarrhoea cases treated with antidiarrhoeals decreased to 10% in 2004-2006, from 
20% initially. 
• Reported compliance with standard treatment guidelines for acute diarrhoea has improved 
over time although it remains low. During the most recent period of data collection, 40% of 
children less than 5 years old with acute diarrhoea were treated according to clinical 
guidelines.  
7.2 Patterns in treatment of acute diarrhoea by region, facility 
ownership and prescriber type 
Figure 7.3 presents overall results of acute diarrhoea  treatment  indicators averaged 
by  geographic  region.    Studies  were  classified  according  to  their  origin  into 
categories of World Bank regions. To ensure a reasonable sample size in each group, 
studies  from  the Middle East, North Africa, Europe and Central Asia  region were 
grouped into one Middle East and Central Asia region.  
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Figure 7.3: Diarrhoea treatment indicators including all studies of medicines use for 






























Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results from studies of medicines use suggest that inadequate prescribing for acute diarrhoea 
is present in every region of the world. 
• The percentage of reported cases of acute diarrhoea treated with antibiotics varied across 
regions, from 22% in the Middle East and Central Asia region to over 50% in the East Asia and 
Pacific region.  
• The use of ORT was reported low everywhere, with 60% or less of reported cases of acute 
diarrhoea receiving ORT.  
• Across all regions, the percentage of reported acute diarrhoea cases treated according to 
clinical guidelines was below 50%. 
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Figure  7.4  presents  overall  results  of  prescribing  indicators  for  acute  diarrhoea 
averaged  by World Bank  income  level  of  the  countries  in which  the  studies were 
conducted.  
Figure 7.4: Diarrhoea treatment indicators including all studies of medicines use for 






























Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• Results from studies of medicines use suggest similarities in the treatment of acute diarrhoea 
across regions at different income level.   
• Percentages of diarrhoea cases treated with antidiarrhoeals, with ORT, and percentage of 
patients treated according to clinical guidelines were similar in all three categories of countries. 
• However, the percentage of diarrhoea cases treated with antibiotics was twice as high in 
studies from low and lower-middle income countries than in studies from upper-middle and 
high income countries. 
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Figure  7.5  presents  overall  results  of  acute  diarrhoea  treatment  indicators  by 
prescriber type.  
Figure 7.5: Diarrhoea treatment indicators including all studies of medicines use for 






























MD Paramedic or Nurse Pharmacy Staff, Other, or Unspecified  
 
Key Points: 
• Results from studies of medicines use suggest that prescribing for acute diarrhoea by 
paramedical health workers/nurses may be slightly better than by medical doctors according to 
all four practices assessed. 
• The percentage of diarrhoea cases treated with antidiarrhoeals was lowest when the reported 
prescriber was a paramedical health worker/nurse.  
• The percentage of diarrhoea cases treated with ORT was lowest when the reported prescriber 
was not a nurse or a medical doctor. 
• The percentage of reported acute diarrhoeas treated according to clinical guidelines was below 
40%, regardless of the type of prescriber. 
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Figure 7.6 presents results for acute diarrhoea treatment indicators by ownership of 
health‐care  facility.  Only  data  from  studies  measuring  prescribing  of  physicians, 
nurses,  and  paramedics  are  included  in  the  figure.  No  studies  that  measured 
prescribing  by  these  trained  health  providers  in  the  private  not‐for‐profit  sector 
collected data  for  the  acute diarrhoea  treatment  indicators  in  this  category,  so  the 
graph does not present any results for this sector. 
Figure 7.6: Diarrhoea treatment indicators including all studies of medicines use for 































Public Private, for profit Private, not for profit  
 
Key Points: 
• Results from studies of medicines use in acute diarrhoea suggest substantially better 
prescribing patterns by physicians, nurses, and paramedics in public health-care facilities than 
in private for-profit health-care facilities.  
• The percentage of reported cases of diarrhoea treated with ORT was much higher in studies 
from public health-care facilities (62%) compared to private for-profit health-care facilities 
(41%).    
• The percentages of diarrhoea cases treated with antidiarrhoeals and antibiotics were much 
lower in studies from public health-care facilities than in studies from private for-profit health-
care facilities.  
• The percentage of acute diarrhoea cases treated according to clinical guidelines was only 40% 
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Figure  7.7  summarizes  the  availability  of  medicines  to  treat  diarrhoeal  illness  in 
studies that focused on the treatment of diarrhoea. 
Figure 7.7: Availability of key medicines in studies of medicines use for acute diarrhoea, 





















Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• The availability of key medicines to treat acute diarrhoea was below 90% in studies from all 
regions except the East Asia and Pacific region. 
• Availability of medicines was particularly low in health facilities in Latin America and the 
Caribbean (58%) as well as in Middle East and Central Asia and South Asia (62%). 
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8. TREATMENT OF MALARIA 




The  indicator  ‘percent of malaria  cases given  recommended  antimalarial’  accounts 
for  the choice of antimalarial medicine:  it does not  take  into consideration whether 






Figure 8.1: Prescribing of recommended antimalarial treatment over time, including all 





















% Malaria Cases Treated with Recommended Antimalarials  
 
Key Points: 
• Results from studies reporting antimalarial use suggest that patterns of antimalarial 
prescribing worsened during the overall period of data collection. 
• One possible explanation for this negative trend may be changes in national malaria treatment 
policy that have occurred in the last 10 years aimed at fighting antimalarial resistance and the 
lag time inherent in implementing these changes. 
• The percentage of reported malaria cases treated with recommended antimalarials in studies 
of antimalarial use was only 51% during the period 2004-2006.  
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Recent  emphasis  on  malaria  control  and  also  the  integrated  management  of 




Figure 8.2: Prescribing of recommended antimalarial treatment over time, comparing 





















% Malaria Cases Treated with Recommended Antimalarials, Children <5 years only
% Malaria Cases Treated with Recommended Antimalarials, General Population  
 
Key Points: 
• Results from studies of medicines use in malaria suggest comparable trends in prescribing 
antimalarials for children < 5 years and the general population (adults and children) during 
recent periods of data collection.   
• Between 1995 and 2006, the percentage of malaria cases treated with recommended 
antimalarials in children less than 5 years old increased by about 10%, to just under 60% of 
cases. 
• Overall, the adequacy of antimalarial prescribing, as reported in studies of antimalarial use, 
has worsened since the 1982-1994 time period both in the general population (adults and 




primary  care  where  the  main  prescriber  was  a  nurse  or  paramedical  health‐care 
worker. Thus a description of prescribing patterns by region or prescriber type was 
not possible.  
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9. INAPPROPRIATE ANTIBIOTIC USE 
This section focuses on studies that reported results about antibiotic treatment. Two 
indicators  of  appropriateness  of  antibiotic  use  extracted  from  this  subgroup  of 











9.1 Inappropriate antibiotic prescribing over time 
Figure 9.1 presents the two indicators of antibiotic treatment over the chronological 
periods of data collection.  





















% Antibiotics Prescribed in Underdosage
% Patients Prescribed Antibiotics Inappropriately  
 
Key Points: 
• Results suggest a large, persistent and growing problem of inappropriate use of antibiotics. 
• The percentage of patients prescribed antibiotics inappropriately increased to over 50% in 
studies conducted between 2001 and 2006, up from 40% in earlier studies.  
• The percentage of antibiotics prescribed in underdosage remained over 50% in all time 
periods.    
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9.2 Inappropriate antibiotic prescribing by region, facility 
ownership and type of prescriber 
Figure  9.2  presents  overall  results  of  both  indicators  of  inappropriate  antibiotic 
treatment indicators by geographic region. The sample size of studies in the Middle 
East  and Central Asia  region  for  the  first  indicator  is  too  small  to display  on  the 
graph. 






















Sub-Saharan Africa Latin America and Caribbean Middle East and Central Asia
East Asia and Pacific South Asia  
 
Key Points: 
• Results suggest that inappropriate prescribing of antibiotics is a widespread problem in every 
geographic region. 
• In all regions except Latin America, over 40% of reported prescriptions of antibiotics were 
inappropriate, with countries in South Asia having the highest rates of inappropriate antibiotic 
use. 
• In Latin America, prescribing insufficient doses of antibiotics was reported more frequently 
than in other regions: 67% of antibiotics prescribed were dosed incorrectly. 
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Low Income Lower-Middle Income Upper-Middle & High Income  
 
Key Points: 
• The percentage of antibiotics prescribed in under dosage was slightly higher in studies from 
upper-middle and high income countries; over 60% of prescribed antibiotics in this income 
group were at inappropriately low doses.   
• The lowest rates of patients prescribed antibiotics inappropriately were seen in upper-middle 
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Figure 9.4 presents overall results of antibiotic treatment indicators averaged by type 
of prescriber. 






















MD Paramedic or Nurse Pharmacy Staff, Other, or Unspecified  
Key Points: 
• Results of studies of medicines use suggest unsatisfactory antibiotic prescribing patterns by all 
cadres of health worker.  
• Over 40% of antibiotics were prescribed in underdosage by all types of health providers. 
• The percentage of patients prescribed antibiotics inappropriately was highest when the 




care  facility ownership,  including only  those  studies  that measured prescribing by 
physicians, nurses, or paramedics. The number of studies conducted  in  the private 
not‐for‐profit sector was insufficient to evaluate antibiotic use in this sector. 
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Figure 9.5: Inappropriate prescribing of antibiotics, by health-care facility ownership 






















Public Private, for profit Private, not for profit  
 
Key Points: 
• Results from studies of inappropriate antibiotic prescribing by physicians, nurses, and 
paramedics suggest better antibiotic prescribing patterns in public health-care facilities than in 
private for-profit health-care facilities. 
• The prescribing of antibiotics in under dosage was slightly higher in private for-profit facilities 
than in public facilities (56% versus 53%) and the percentage of patients prescribed antibiotics 
inappropriately was markedly higher in the private for-profit sector (72% versus 45%). 
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10. INTERVENTIONS TO IMPROVE USE OF MEDICINES 
This  section  focuses  on  studies  examining  use  of  medicines  that  included  an 
intervention.  These studies varied widely in the types and scope of the interventions 
investigated.    Many  studies  tested  the  impact  of  prospective  efforts  to  improve 
prescribing  in  small  samples  of  health  facilities,  health  providers,  or  patients.  
However, some community case management studies examined the impact of large 
prospectively  designed  interventions  in  improving  how  specific  common  health 
problems  were  managed  in  order  to  reduce  mortality.    The  interventions  in  the 
database  also  include  several  different  types  of  system‐based  interventions, 




10.1 Overview of interventions to improve medicines use 
For the period 1990‐2006, the database includes information about 386 interventions 
to  improve use of medicines that were evaluated  in 317 studies.   Figure 10.1 shows 
the  distribution  of  these  interventions,  classified  according  to  the  component  that 
best captures the nature of the intervention strategy evaluated. 
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• Overall, 37% of the 386 interventions in the database tested an educational programme 
directed at health providers; about half of these interventions also included consumer or 
patient education. 
• One in ten interventions tested community case management strategies aimed at preventing 
mortality from ARI, diarrhoea, or malaria, typically involving provider and community 
education, training of community health workers, and community availability of essential 
medicines. 
• The largest single group of studies represented in the database included surveys to measured 
medicine indicators during the implementation of an NMP, EMP, or another regulatory strategy; 
most commonly these were one time cross-sectional studies to measure whether the policy 
was achieving its intended effects. 
• An increasing number of interventions (13% of those in the database) include enhanced 
supervisory programmes, with or without routine audits of health provider practices; these 
approaches are frequently used in the implementation in the IMCI programme as a strategy to 
improve the performance of lower level health workers. 
 
Although some studies have tested a specific type of single component intervention 
(such  as  a  one‐time  provider  training  seminar),  many  have  incorporated  several 
educational,  managerial,  financial,  or  regulatory  components.  Table  10.1  below 
shows the individual components that were part of these interventions. 
 
Most  interventions  of  every  type  involved  a  mix  of  components.  Only  the 
interventions  that  evaluated  the  effects  of  economic  incentives  directed  at  health 
providers or patients tended not to include other strategies. 
 
Two‐thirds  of  all  interventions  reported  using  printed  educational  materials,  but 
only nine interventions tested the efficacy of these materials as a specific component 
of  the  study.  Generally,  almost  all  studies  with  educational  activities  directed  at 
health providers used  some  type of printed materials;  a  smaller percentage of  the 
behaviour  change  interventions  that  targeted  consumers,  patients,  and  the 
community reported using printed materials. 
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The  interventions  classified as group educational process  incorporated educational 
programmes  for  health  providers,  including  peer  review  or  self‐monitoring  of 
prescribing  practices,  typically  combined  with  guidelines  or  other  printed 
educational materials. One  in  five  of  these  studies  also  included  enhanced  health 
worker  supervision.    Interventions  that  were  classified  as  supervision  with  or 




intervention  components,  reflecting  the  broad‐based  strategies  typically 
implemented as part of  these programmes. Because of  their diversity,  these studies 
are more difficult to characterize. 
Table 10.1: Individual approaches included in different types of interventions  
Intervention type 

































9 2% 100% 0% 0% 0% 0% 0% 0% 11% 0%
Provider education 73 19% 84% 100% 0% 0% 0% 0% 0% 3% 1%
Provider and consumer/ 
patient education
68 18% 84% 100% 100% 0% 4% 29% 0% 3% 0%
Consumer/patient 
education
3 1% 33% 0% 100% 0% 0% 0% 0% 0% 0%
Community case 
management
37 10% 32% 73% 81% 100% 0% 70% 8% 70% 11%
Provider group educational 
process
12 3% 92% 92% 8% 0% 100% 17% 0% 8% 17%
Enhanced supervision +/- 
audit
51 13% 76% 88% 0% 0% 0% 100% 0% 4% 0%
Economic incentives to 
providers / patients
22 6% 5% 9% 0% 0% 0% 5% 100% 0% 0%
EMP, NMP, other national 
policy or regulation
111 29% 60% 64% 33% 0% 1% 40% 14% 91% 6%
All interventions 386 100% 67% 77% 36% 10% 4% 37% 10% 35% 4%
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Figure  10.2  shows  the  types  of  study  designs  that  were  used  to  evaluate  the 
interventions included in this review.    
Figure 10.2: Types of study designs in studies to evaluate medicines use interventions, 




































































• Of the 317 intervention studies included in the database, only 82 (26%) were evaluated using 
a research design that is considered methodologically adequate for drawing reliable 
conclusions about intervention impacts. 
• Overall, 41% of studies were evaluated using post-only without control group designs that did 
not include either a control group or measurement before and after the intervention; another 
18% had pre- and post-measurement but no controls, while 15% used a control group but  
measured the medicines use indicators only after the intervention was completed. 
• The methodologically adequate research designs included randomized controlled trials (n=17, 
5% of studies), time-series with control groups (n=2, 1% of studies) or without control groups 
(n=20, 6% of studies), and pre-post studies with control groups (n=43, 14% of studies). 
 
 
As  shown  in  Figure  10.3,  the  overall  quality  of  studies  testing  interventions  to 
improve  the  use  of medicines  has  not  improved  substantially  over  time,  and  the 
majority of studies are still of poor methodological quality.   
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Acceptable quality (n=82) Poor quality (n=235)  
 
Key Points: 
• There was an increase in the overall volume of reported research on interventions to improve 
medicines use in the mid-1990s, but the number of available studies has declined in the last 
10 years. 
• The quality of the research designs has not improved markedly over time; 25% of studies up 
to the year 2000 had acceptable designs, compared to 28% of studies since then.   
 
 
Table  10.2  presents  data  on  the  distribution  of  the  intervention  research  studies 
included  in  the  database  by  geographic  region,  country  income,  health  facility 
ownership  and  prescriber  type.   Although  there  are  intervention  studies  from  all 
geographic  regions, about one  third of  the studies of acceptable quality come  from 
Sub‐Saharan Africa, another third from South Asia, and an additional 20% from the 
Asia Pacific region.  Relatively little well‐designed research on improving medicines 
use  has  been  reported  from  the  non‐industrialized  countries  in  Latin  America, 
Europe, Central Asia, or the Middle East.  About 70% of well‐designed studies have 
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Table 10.2: Distribution of intervention studies by World Bank Region, country 
income, health facility ownership, prescriber type 
Acceptable quality Poor quality All studies
Number of studies 82 235 317
World Bank Region
Sub-Saharan Africa 28 103 131
34% 44% 41%
Europe and Central Asia 2 6 8
2% 3% 3%
Latin America and Caribbean 6 38 44
7% 16% 14%
Middle East and North Africa 3 17 20
4% 7% 6%
South Asia 27 34 61
33% 14% 19%
East Asia and Pacific 16 37 53
20% 16% 17%
World Bank Country Income
Low income 57 137 194
70% 58% 61%
Lower-middle income 19 63 82
23% 27% 26%
Upper-middle & high income 6 35 41
7% 15% 13%
Health Facility Ownership
Private, for profit 12 19 31
15% 8% 10%
Private, not for profit 1 1 2
1% 0% 1%
Public 50 179 229
61% 76% 72%
Not applicable, self-medication 13 21 34
16% 9% 11%
Unspecified 6 15 21
7% 6% 7%
Prescriber Type
MD 19 52 71
23% 22% 22%
Paramedic or nurse 39 141 180
48% 60% 57%
Pharmacy staff 3 6 9
4% 3% 3%
Other 16 29 45
20% 12% 14%
Unspecified 5 7 12
6% 3% 4%  
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In addition to study design, another key aspect of methodological quality of a study 
is  the overall  size of  the  samples of prescribing and dispensing episodes assessed, 





focused  and  targeted  specific  providers  and  patients,  while  others  represented 





Table 10.3: Numbers of patients and health facilities included in the basic 




facilities <100 100-999 1000-9999 10,000 + NA Number Percent
1 0 0 0 0 1 1 1%
2-5 0 1 4 0 1 6 7%
6-10 1 3 3 1 1 9 11%
11-20 0 2 7 3 2 14 17%
21-99 0 5 13 8 3 29 35%
100 + 0 4 2 1 0 7 9%
NA 0 2 2 3 9 16 20%
Total Number 1 17 31 16 17 82 100%
Percent 1% 21% 38% 20% 21% 100%
1 0 8 3 4 0 15 6%
2-5 1 7 1 0 0 9 4%
6-10 1 10 2 0 1 14 6%
11-20 2 8 10 1 2 23 10%
21-99 16 75 15 3 13 122 52%
100 + 0 13 6 1 4 24 10%
NA 2 7 8 3 8 28 12%
Total Number 22 128 45 12 28 235 100%
Percent 9% 54% 19% 5% 12% 100%















examining  the effects of  interventions, we will examine  the sensitivity of  results  to 
exclusion of  the 11 well‐designed  interventions  tested  in 8 studies with  fewer  than 
100 patients or 6 health facilities.  
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Table  10.4  displays  the  wide  array  of  indicators  that  have  been  measured  in 
intervention studies.   
Table 10.4: Proportion of intervention studies measuring each medicines use 
outcome recorded in the database, by study quality 
Indicator group Acceptable 
quality
Poor quality All studies
Total number of studies 82 235 317
Appropriate prescribing
Avg. no. medicines per patient 61% 28% 36%
% patients prescribed antibiotics 56% 27% 35%
% patients prescribed injection 41% 20% 25%
% injections inappropriate 2% 1% 1%
% prescribed from EML 20% 11% 14%
% prescribed by generic name 23% 11% 14%
% patients treated by STG 48% 59% 56%
% treated without medicines 1% 2% 2%
Avg. drug cost per patient 22% 12% 15%
% patients prescribed vitamins/tonics 6% 2% 3%
Appropriate patient care
Avg. consultation time 12% 9% 9%
Avg. dispensing time 10% 7% 8%
% patients given dosing instructions 13% 34% 29%
% patients who know regimen 11% 43% 35%
% medicines adequately labeled 10% 7% 8%
% patients satisfied with treatment 0% 0% 0%
Health facility resources
% facilities with EML available 9% 4% 5%
% facilities with STG available 1% 20% 15%
% facilities with impartial information 1% 1% 1%
% key medicines available 23% 26% 25%
% specific recommended medicines available 0% 23% 17%
% prescribed medicines dispensed 11% 10% 10%
Community case management
Overall mortality rate 9% 2% 4%
ARI mortality rate 4% 3% 3%
Diarrhoea mortality rate 2% 1% 1%
Malaria mortality rate 1% 0% 0%
Treatment of specific conditions
% with antidiarrhoeal for diarrhoea 23% 13% 15%
% with antibiotic for diarrhoea 33% 20% 24%
% with ORT for diarrhoea 39% 31% 33%
% URTI treated with antibiotic 28% 18% 21%
% antibiotics for pneumonia 17% 33% 29%
% cough syrup for ARI 12% 4% 6%
% prescribed appropriate antimalarial 9% 19% 16%
% iron-folate in pregnancy 4% 0% 1%
Antibiotic use
% antibiotics inappropriate 7% 20% 16%
% antibiotics underdosed 4% 2% 3%
% drug cost on antibiotics 0% 0% 0%
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The most  common behaviours  targeted by well‐designed  interventions are general 
indicators  of  appropriate  prescribing,  including  number  of  medicines  per  patient 
(60%  of  interventions),  prescribing  of  antibiotics  (55  percent),  and  prescribing 
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• The database contains information about 121 interventions tested in 82 well-designed studies. 
• Two thirds of well-designed studies (a total of 70 interventions) assess the impacts of provider 
education with or without consumer education or enhanced supervision. 
• Reflecting the difficulty of designing a valid longitudinal policy assessment, the database 
contains only 14 adequately designed studies of the impacts of Essential Medicines 
Programmes, National Medicines Policies, or other national regulations. 
• Despite the importance of economic factors as determinants of medicines use among both 
prescribers and patients, there are only 7 methodologically sound assessments of the impacts 
of changes in economic incentives. 
10.2 Impact of well-designed interventions to improve medicines 
use 
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Figure  10.5  shows  estimates  of  the  first  measure  of  effect,  namely,  the  greatest 
percentage  changes  attributed  to  all  well‐designed  interventions,  as  well  as  the 
median effect size across all studies in each intervention group.  All indicators have 
been scaled such that a positive change is desirable. 
Figure 10.5: Largest reported percentage change in any study outcome for all 
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• The median of the largest effect sizes across all 121 studies was 21%, a magnitude of 
improvement consistent with prescribing interventions from industrialized countries.  However, 
interventions reported a wide range of effects (25th: 75th percentiles were 14%:32%).  Overall 
23 of 121 studies reported positive effects lower than 10%. 
• Excluding the 11 interventions with small samples had no effect on results; the median of the 
largest effect size remained 21% (25th:75th percentiles 13%:33%). 
• Interventions built on group processes for health providers (such as peer review or group STG 
development) demonstrated the highest median positive effect (37%), and only one of the 
eight interventions reported a positive change of lower than 19%. 
• The lowest median effect size (8%) was for interventions using only printed educational 
materials, a finding that is consistent with the failure of print materials to change prescribing in 
systematic reviews from industrialized countries.  While a component of most interventions, 
printed materials tend to be ineffective by themselves.   
• Interventions primarily based on the use of economic incentives to change prescribing reported 
the second lowest median effect size. 
• For community case management intervention, approximately half the studies examined 
mortality rate and half prescribing outcomes; however, the median largest effect sizes in both 
types of study were similar.   
• Interventions using provider and consumer education to improve the use of medicines included 
studies with and without enhanced supervision. The median largest effect size for provider and 
consumer education without supervision (13 studies) was 18%  (25th:75th percentiles 
7%:21%) and with supervision (7 studies) was 40% (25th:75th percentiles 23%:54%).  
• The intervention group covering EMP, NMP, other national policy or regulation includes a 
diverse set of interventions. However, the EMP group differs from the other groups in having 
an element of medicines supply in the intervention. The median largest effect size for EMP (7 
studies) was 27%  (25th:75th percentiles 20%:45%), for NMP (6 studies) was 15% (25th:75th 
percentiles 14%:24%) and for regulation (1 study) was 24%. 
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Of the 121 interventions reported in Figure 10.5, 109 focused primarily on improving 
prescribing  indicators,  while  the  remaining  12  studies  measured  the  effects  on 
mortality  rates  of  interventions  to  improve  treatment  of  malaria,  pneumonia,  or 
diarrhoea.   The studies  focused on mortality reduction  included 9 community case 
management  studies,  2  studies  evaluating  national  medicines  policies,  and 
1 intervention  involving  provider  and  consumer  education.    The  median  largest 
effect sizes for the prescribing improvement and mortality reduction studies (21% vs. 
19%  respectively)  were  roughly  similar.    However,  given  the  small  number  of 




Figure  10.6  shows  the  estimated  impacts  of  all  well‐designed  prescribing 
improvement  interventions  for  the second summary measure of effect, namely,  the 
median  change across all prescribing outcomes  for a given  study.   Once again, all 
indicators have been scaled such that a positive change is desirable.  On average, the 
database  contains  information  on  4.0  outcomes per  study.    Studies  examining  the 
impact  of  consumer  education  reported  substantially  fewer  prescribing  outcomes 
(2.0) than other types of intervention, while studies of printed educational materials 
(7.4) reported substantially more. 
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Figure 10.6:  Median reported percentage change across all study outcomes for 
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• The median across all studies of the study-specific median change in outcomes was 9% 
(25th:75th percentiles 2%:20%), or less than half the size of the largest observed effect.  
Overall, 31 of 109 studies reported median effect sizes of 5% or less across all of the 
outcomes measured.   
• Excluding the 11 studies with small sample sizes from the analysis again had no discernable 
effect on the median or range of effect sizes; the median effect size across the remaining 
98 studies was 9% (25th:75th percentiles 3%:19%). 
• Interventions that used a combination of provider and consumer education to improve use of 
medicines report a median 16% improvement across the outcomes they measured (an 
average of 2.4 outcomes per study); this is a 9% greater median positive impact than the 25 
studies (measuring an average of 4.6 outcomes) which tested provider education alone. 
• Many educational interventions targeting health providers include supervision as either a major 
or minor intervention component.  On average, educational interventions targeting health 
providers that included enhanced supervision as either a major or minor intervention 
component (median improvement 14%, 25th:75th percentiles 7%:22%) had a 7% larger effect 
size than those that did not (median improvement 7%, 25th:75th percentiles 4%:16%). 
• For the intervention group covering provider and consumer education to improve the use of 
medicines, the median effect size for provider and consumer education without supervision 
(12 studies) was 9%  (25th:75th percentiles, -1%:+18%) and with supervision (7 studies) was 
24% (25th:75th percentiles 18%:28%).  
• For the intervention group covering EMP, NMP, other national policy or regulation, the median 
improvement in prescribing was 5% (for an average of 4.1 outcomes), suggesting that these 
broad based, multidimensional programmes may have modest positive impacts on an array of 
outcomes. However, within this group, the median effect size for EMP (5 studies) was 15%  
(25th:75th percentiles 1%:45%), for NMP (6 studies) was 5% (25th:75th percentiles 
0%:15%) and for regulation (1 study) was 5%. 
 
The  median  improvement  across  all  reported  indicators  provides  a  more  conservative 
estimate of  intervention  impacts than the  largest reported  impact.   In subsequent analyses, 
we will adopt this conservative approach by reporting only the median effects across all the 
prescribing indicators reported in each study. 
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10.3 Comparison of paediatric and non-paediatric interventions  
The database contains  two distinct groups of  interventions: 226 studies  focused on 
improving  the use of medicines  for  treating  common health problems  among  sick 
children;  and  160  studies  that  examine  more  general  prescribing  improvement 
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Key Points: 
• Overall, 74 of the 160 non-paediatric studies (46%) had acceptable research designs;  73 of 
the 74 well-designed interventions targeted prescribing or patient care improvements, while 1 
intervention targeted mortality reduction. 
• Most of the non-paediatric interventions with poor research designs involved evaluations of 
EMP, NMP, or other national policies; only 1 in 6 of these interventions had a design that 
allowed it to be included in summary analyses of intervention effects. 
• Over 70% of the studies of the impact of economic incentives on use of medicines also had 
poor research designs, with only 6 studies strong enough to be included in the summary 
analysis of impacts. 
• The largest number of well-designed non-paediatric studies were those that measured the 
impacts of enhanced supervision and practice audits (19 studies), followed by studies of 
provider education (16 studies) or provider plus consumer education (10 studies). 
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Key Points: 
• Only 21% of the 226 paediatric intervention studies had acceptable research designs, in 
contrast to nearly half of the non-paediatric studies; 36 of the 47 well-designed interventions 
targeted prescribing or patient care improvements, while 11 interventions targeted mortality 
reduction. . 
• A very large proportion of the evaluations of EMP, NMP, or other national policies had 
unacceptable research designs; only 6% of these interventions could be included in summary 
analyses of intervention effects. 
• In contrast to non-paediatric studies, only a small proportion of the studies of enhanced 
supervision and provider education had acceptable research designs. 
• The largest group of well-designed paediatric studies were interventions that focused on 
assessing the impact of community case management for ARI, diarrhoea, or malaria on 
mortality (9 studies) or prescribing (4 studies). 
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Figures 10.9 and 10.10 present the summary results separately for the non‐paediatric 
and paediatric  interventions.   These figures once again exclude the 12  interventions 
focused mainly on mortality  reduction, and  they use  the median of all prescribing 
outcomes as the summary measure of effect. 
Figure 10.9: Median reported percentage change across all prescribing outcomes for 
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• The median effect size in the non-paediatric interventions was 7% improvement in study 
outcomes (25th:75th percentiles 1%:15%). Overall, 25 of the 73 studies reported a median 
change of 5% or less across all prescribing outcomes. 
• Although several categories have only a few studies, the overall estimates of median effects 
for most categories are modest (10% or less).  
• The largest median effects were observed for interventions that combined several components, 
including interventions involving provider and consumer education (a median improvement in 
the indicators measured across studies of 17%), a provider group educational process (13%), 
followed by enhanced supervisory programmes (9%) and provider education alone (6%). 
• Among the interventions that combined provider and consumer education, the three which 
included a supervisory component reported a median improvement of 27% in prescribing 
indicators, while the seven that did not include supervision reported a median improvement of 
11%. 
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Figure 10.10: Median reported percentage change across all prescribing outcomes for 
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• The median reported effect size was a 16% improvement in study outcomes (25th:75th 
percentiles 7%:26%); this represents a 9% greater magnitude of change than that observed 
in the non-paediatric studies. Overall, 7 of the 36 studies reported a median change of 5% or 
less across all prescribing outcomes. 
• There was a very large effect size in the single well-designed study (classified as an EMP 
intervention - see figures 10.5 and 10.6), which examined the effects of the implementation of 
the national IMCI programme in Bangladesh on a range of prescribing indicators.  The poor 
quality of research on the impacts of these types of national policies makes it impossible to 
know whether this finding is at all generalizable. 
• All types of educational interventions to improve paediatric prescribing (whether directed at 
providers alone, consumers alone, or both providers and consumers) had median effect sizes 
between 11% and 16%.  
• Among the interventions that combined provider and consumer education, the four which 
included a supervisory component reported a median improvement of 18% in prescribing 
indicators, while the five that did not include supervision reported a median improvement of 
6%. 
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10.4 Comparison of paediatric interventions targeting different 
conditions 
In addition  to differences  in  intervention design, paediatric  interventions also vary 
by  the health problem  targeted.   Earlier paediatric studies reported  in  the database 
tended  to  focus on  improving  treatment  for one of  three common health problems: 
acute  respiratory  infections,  diarrhoea,  or  malaria.    In  recent  years,  paediatric 
interventions have tended to address all three of these common infections together in 




Figure  10.11  presents  the  quality  of  the  research  designs  for  the  paediatric 
interventions  targeting  common  infections  categorized  in  these  four  groups  of 
intervention studies, while Figure 10.12 compares the effects sizes observed for these 
interventions. 
Figure 10.11: Methodological quality of prescribing improvement interventions targeting 
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Key Points: 
• There are four distinct clusters of well-designed paediatric studies in the database, those 
focused on improving prescribing and patient care for ARI, diarrhoea, and malaria, and a more 
recent group of studies assessing the impacts of the implementation of IMCI programmes.  
• Although IMCI evaluations comprise the largest group of paediatric studies, only 24% of these 
34 studies have adequate research designs. 
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Figure 10.12: Median reported percentage change in prescribing outcomes in well-
designed paediatric prescribing improvement interventions targeting common 
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• The largest median improvement in prescribing outcomes (29%) was observed for studies 
focused on improving malaria treatment; all 5 of these studies had median improvements in 
study outcomes between 23% and 39%. 
• Overall, well-designed ARI and IMCI studies resulted in similar median improvements in key 
prescribing outcomes of 14% and 18% respectively; however 4 of 14 ARI studies reported 
median improvements of less than 5% in the prescribing outcomes studied, while only 1 of 
8 IMCI studies had a median improvement that low. 
• The 8 studies focused on prescribing for paediatric diarrhoea reported the lowest median 
improvement in study outcomes of 7%, substantially lower than other types of studies 
targeting paediatric infections.  
 
  Discussion and Recommendations 
–  85  – 
11. DISCUSSION AND RECOMMENDATIONS 
This  fact  book  summarizes  the  information  contained  in  a  database  of  existing 
published literature and unpublished reports related to medicines use. This database 
was  created  by  WHO  to  monitor  the  use  of  medicines  in  primary  care  and  to 
measure  the  impacts  of  interventions  aimed  at  improving  medicines  use  in 
developing and  transitional  countries. The analysis of  existing published  literature 
and unpublished  reports provides an alternative  to direct monitoring of medicines 
use,  especially  since  many  countries  do  not  do  so  in  any  systematic  way.    This 
approach  can  focus  on  general  medicines  use  and  on  the  treatment  of  the  most 
prevalent conditions  in primary care, and  it can evaluate  the use of medicines over 
specific periods of  time,  in different  regions, and by  types of  facility or prescriber. 
WHO undertook an analysis of  the database on medicines use, and  the  results are 
presented  in  this  Fact  Book.  The  findings  provide  adequate  information  to  draw 
several  conclusions about  the use of medicines  in primary  care  in developing and 
transitional countries.  
11.1 Major findings 
The WHO database constitutes a  large body of collected evidence about medicines 
use.  It  contains data  collected  in 97  countries over a period of 25 years, about 856 
study populations. Because of  long‐standing support for work on medicines use by 
WHO and donor organizations,  the majority of data  come  from public health‐care 
facilities. The number of studies conducted  in pharmacy shops and  in non‐licensed 




In general,  the  results  are  similar  in  all geographic  regions  and  time periods,  and 
suggest  that  prescribing  patterns  have  not  improved  in  any  systematic  way  over 
time. During  the most  recent period of data  collection,  fewer  than half of patients 
were  treated  according  to  clinical  guidelines  for  the  common  diseases  seen  in 
primary care settings. The use of antibiotics has increased over time to reach 50% of 
prescriptions in primary care studies with both percentages of antibiotics prescribed 
inappropriately  and  in  underdosage  increasing  to  over  half  of  antibiotic 
prescriptions.  Studies  in  acute  respiratory  tract  infection  and malaria  suggest  that 
medicines use in these conditions may have deteriorated somewhat over time. Over 
two‐third  of  all  cases  of  upper  respiratory  tract  infection  received  antibiotics 
unnecessarily,  while  less  than  80%  of  pneumonia  cases  were  treated  with  an 
appropriate antibiotic  in most  recent  studies. During  the  same period, only half of 
malaria  cases  received  appropriate  antimalarials.  On  the  other  hand,  some 
encouraging  trends  were  observed  with  regards  to  the  percentage  of  medicines 
prescribed from EML/formularies and the use of generics. In addition, the percentage 
of  children  receiving ORT  for diarrhea doubled over  time, although  reaching only 
60%; a substantial decrease was observed in the use of antidiarrhoeals.  
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Most studies report results from the public sector. Nevertheless, results suggest that 
the use of medicines  in  studies  in public health‐care  facilities, while  still deficient, 
was  substantially  better  than  in  private  facilities:  this  was  true  for  WHO/INRUD 
prescribing  indicators  and  also  for ARI,  diarrhoea  and  appropriate  antibiotic  use. 
These results may  indicate a high proportion of clinically  inefficient and  ineffective 
care  in  settings where  the  private  sector  carries  out  the majority  of  primary  care 
prescribing. In contrast, patient care indicators appeared to be better in studies from 
the private  sector, where  consultation  and dispensing  times were  longer,  labelling 
was  more  often  adequate,  and  patient  knowledge  of  dosing  was  also  better. 
Prescribing  by paramedical  and nursing  staff was  similar  to  that  of doctors when 
measured by  the WHO/INRUD  indicators,  as well  as  specific  indicators  related  to 
treatment of ARI, diarrhoea and  to  the  inappropriate use of antibiotics. The poorer 






addition  to  the  small  number  of  studies,  the  research  topics  and  approaches  are 
fragmented, and research studies are often designed and conducted without  taking 






In  general,  the  levels  and  patterns  of  intervention  impacts  are  similar  to  those 
reported  in  systematic  reviews  of  intervention  studies  conducted  in  the 
industrialized world.24,25   As has been  found  in a majority of systematic  reviews of 
interventions  in  industrialized  countries,  interventions  that  involved  several 
components appeared  to have greater  effects on  clinical practice.26,27    Interventions 
with multiple  components  that  involved  education  for  both  health  providers  and 
consumers,  provider  group  educational  processes,  and  especially  interventions 
involving enhanced supervision of prescribing practice appeared  to be particularly 
promising.  Given their widespread implementation, there is a need to conduct more 
rigorous  longitudinal  research  of  the  effects  of  National  Medicines  Policies  and 
Essential Medicines Programmes. 
11.2 Remaining gaps in knowledge 
While the database of medicines use surveys has provided much information about 
prescribing in the public primary care sector, much still remains unknown about the 
private  sector.  The  quality  of  care  provided  by  private  practitioners  including 
clinicians,  pharmacists,  pharmacy  assistants  and  informal medicine  sellers  remain 
largely unknown.  
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No attempt was made  to collect data on use of medicines  in  inpatient or  specialty 
care, particularly for chronic disease; this remains a large gap in current knowledge 
that  remains  to be  investigated.  In  addition,  almost no data  are  available  on  cost‐
effectiveness of interventions to improve medicines use, and very few of the studies 
entered  into  the database had any costing data that could be used  to estimate cost‐
effectiveness.    
 
It  is  important  to  note  that  there  are  several  important  aspects  of  medicines  use 
which are not yet abstracted  into  the database,  including geographic and  financial 
access  to  and  affordability  of  medicines,  safety  of  medicines  use;  health‐seeking 
behaviour  and  self‐medication  practices;  accuracy  of  diagnostic  decision‐making;  
and medicines use in hospital inpatient settings.  
 
The proportion of policies  and planned  interventions  targeting medicines use  that 
are evaluated with methodologically adequate research designs is very low and the 
evidence  base  for  recommending  effective  intervention  approaches  is  growing 
slowly and haphazardly. National governments need to be more committed to well‐




11.3.1 Maintaining, updating, and disseminating the database 
Information on access to medicines, affordability, and appropriateness of medicines 
use,  and  on  the  impacts  of  interventions  designed  to  improve  the  medicines 
situation,  is  crucial  for  decision  making  at  national  and  international  levels.    To 
develop  strategies  for  improving  the  medicines  situation  for  the  most  vulnerable 
populations,  global  and  domestic  policy  makers  need  to  know  the  status  of 
medicines  use, where  gaps  in  knowledge  exist,  and which  interventions  are most 
likely to succeed.  
 
At present, no process  for  systematically compiling and evaluating  information on 
medicines use  exists globally. Without  such data,  stakeholders will have difficulty 
grasping  the  severity  of  the  problem  of  inappropriate  use  and  will  have  little 
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% Medicines from EML or Formulary
1982-1991 6 66.0 40.0 86.0
1992-1994 23 83.7 68.0 94.4
1995-1997 38 73.6 55.3 88.1
1998-2000 50 71.2 45.7 88.1
2001-2003 36 90.2 78.7 96.0
2004-2006 9 89.4 82.5 92.5
% Medicines Prescribed by Generic Name
1982-1991 11 44.0 16.0 80.0
1992-1994 43 59.0 42.8 72.0
1995-1997 44 49.0 33.6 74.6
1998-2000 53 55.0 15.4 76.0
2001-2003 27 60.0 48.6 84.0
2004-2006 14 72.3 27.0 83.7
% Patients with an Antibiotic Prescribed
1982-1991 38 42.8 28.4 54.0
1992-1994 62 43.9 34.0 57.1
1995-1997 72 48.8 36.3 56.4
1998-2000 71 46.9 35.0 56.0
2001-2003 75 46.7 35.8 58.1
2004-2006 24 46.4 32.0 55.3
% Patients with Injection Prescribed
1982-1991 28 23.7 13.6 48.0
1992-1994 51 20.0 11.5 34.9
1995-1997 61 20.0 11.1 28.0
1998-2000 58 20.6 9.1 31.0
2001-2003 52 21.9 8.1 34.1
2004-2006 18 19.0 7.6 37.1
% Treated According to Clinical Guidelines
1982-1991 14 49.4 41.0 77.0
1992-1994 51 28.7 12.4 48.0
1995-1997 55 33.0 16.2 50.0
1998-2000 33 33.9 13.7 46.4
2001-2003 39 43.0 18.1 61.8
2004-2006 13 39.3 21.0 58.0
Average Number of Medicines per Patient
1982-1991 38 2.0 1.4 2.4
1992-1994 78 2.5 2.0 3.4
1995-1997 85 2.4 2.0 3.0
1998-2000 86 2.6 2.1 3.2
2001-2003 66 2.7 2.2 3.4
2004-2006 17 2.5 2.2 2.8
Figure 4.1: WHO/INRUD prescribing indicators, by time period
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% Medicines from EML or Formulary
Sub-Saharan Africa 67 87.8 69.0 94.0
Latin America and Caribbean 16 71.4 43.0 85.3
Middle East and Central Asia 13 79.4 46.7 95.0
East Asia and Pacific 26 71.7 46.5 85.8
South Asia 40 84.0 58.5 89.7
% Medicines Prescribed by Generic Name
Sub-Saharan Africa 89 60.0 36.1 80.0
Latin America and Caribbean 14 67.3 52.0 74.0
Middle East and Central Asia 25 42.8 24.3 69.0
East Asia and Pacific 15 64.5 33.2 78.7
South Asia 49 44.0 15.4 69.8
% Patients with an Antibiotic Prescribed
Sub-Saharan Africa 135 47.0 38.0 55.5
Latin America and Caribbean 28 39.3 30.9 65.6
Middle East and Central Asia 42 45.3 30.5 60.9
East Asia and Pacific 45 42.5 27.6 51.6
South Asia 92 49.1 37.2 57.0
% Patients with Injection Prescribed
Sub-Saharan Africa 124 27.5 17.6 38.0
Latin America and Caribbean 14 13.2 10.5 24.0
Middle East and Central Asia 33 17.0 8.0 30.0
East Asia and Pacific 34 14.8 7.0 31.7
South Asia 63 11.5 5.1 22.0
% Treated According to Clinical Guidelines
Sub-Saharan Africa 106 43.2 19.0 62.0
Latin America and Caribbean 28 39.3 21.5 52.2
Middle East and Central Asia 17 35.7 29.0 46.4
East Asia and Pacific 25 29.5 13.7 42.9
South Asia 29 28.7 12.5 41.0
Average Number of Medicines per Patient
Sub-Saharan Africa 145 2.6 2.1 3.2
Latin America and Caribbean 32 1.8 1.3 2.3
Middle East and Central Asia 51 2.6 2.1 3.2
East Asia and Pacific 47 3.0 2.4 3.7
South Asia 95 2.5 2.1 2.9










% Medicines from EML or Formulary
Low Income 103 86.0 67.0 93.9
Lower-Middle Income 38 75.1 56.0 91.2
Upper-Middle & High Income 21 43.9 38.5 79.4
% Medicines Prescribed by Generic Name
Low Income 130 60.8 36.0 78.0
Lower-Middle Income 37 57.0 24.3 71.6
Upper-Middle & High Income 25 36.0 12.5 57.5
% Patients with an Antibiotic Prescribed
Low Income 224 48.7 37.7 57.1
Lower-Middle Income 72 42.8 34.5 53.5
Upper-Middle & High Income 46 38.2 25.5 55.0
% Patients with Injection Prescribed
Low Income 186 23.2 13.0 37.1
Lower-Middle Income 54 15.0 8.5 30.0
Upper-Middle & High Income 28 11.0 7.7 24.1
% Treated According to Clinical Guidelines
Low Income 134 35.0 17.0 58.0
Lower-Middle Income 49 35.0 15.0 45.0
Upper-Middle & High Income 22 42.3 31.0 65.2
Average Number of Medicines per Patient
Low Income 233 2.5 2.0 3.2
Lower-Middle Income 80 2.6 2.2 3.3
Upper-Middle & High Income 57 2.3 1.8 2.6
Figure 4.3: WHO/INRUD prescribing indicators, by World Bank income level
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% Treated According to Clinical Guidelines
Sub-Saharan Africa 1982-1994 29 46.3 21.0 78.3
1995-2000 48 27.4 11.5 57.2
2001-2006 29 48.1 23.2 62.0
Latin America and Caribbean 1982-1994 13 32.2 22.0 44.0
1995-2000 10 47.5 35.0 61.0
2001-2006 5 39.3 14.7 51.4
Middle East and Central Asia 1982-1994 4 29.9 3.5 55.8
1995-2000 8 32.5 23.0 44.7
2001-2006 5 38.9 35.6 40.5
East Asia and Pacific 1982-1994 7 25.0 12.4 45.0
1995-2000 11 29.5 5.0 38.2
2001-2006 7 36.3 15.4 58.0
South Asia 1982-1994 12 28.6 13.4 39.4
1995-2000 11 33.3 23.1 49.0
2001-2006 6 14.3 2.6 51.6










% Medicines from EML or Formulary
MD 63 73.0 47.0 90.8
Paramedic or Nurse 86 87.4 68.0 94.0
Pharmacy Staff, Other, or Unspecified 20 64.5 44.0 83.0
% Medicines Prescribed by Generic Name
MD 84 37.9 15.4 68.0
Paramedic or Nurse 100 64.4 49.3 80.8
Pharmacy Staff, Other, or Unspecified 15 48.0 36.0 71.6
% Patients with an Antibiotic Prescribed
MD 134 48.6 30.6 62.3
Paramedic or Nurse 175 48.0 38.0 55.0
Pharmacy Staff, Other, or Unspecified 45 37.0 19.7 46.7
% Patients with Injection Prescribed
MD 90 17.3 7.8 34.9
Paramedic or Nurse 161 21.9 11.0 34.1
Pharmacy Staff, Other, or Unspecified 31 23.0 11.0 30.0
% Treated According to Clinical Guidelines
MD 42 37.2 19.5 51.6
Paramedic or Nurse 135 39.2 21.0 59.3
Pharmacy Staff, Other, or Unspecified 29 13.5 3.0 42.8
Average Number of Drugs per Patient
MD 158 2.6 2.2 3.2
Paramedic or Nurse 180 2.4 2.0 3.2
Pharmacy Staff, Other, or Unspecified 45 2.2 1.4 2.8
Figure 4.5: WHO/INRUD prescribing indicators by prescriber type
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% Medicines from EML or Formulary
Public 104 88.0 74.3 94.0
Private, for profit 19 52.6 38.0 67.0
Private, not for profit 8 77.0 58.9 84.0
% Medicines Prescribed by Generic Name
Public 131 60.6 36.1 80.0
Private, for profit 24 13.3 7.8 50.4
Private, not for profit 10 62.5 52.0 75.5
% Patients with an Antibiotic Prescribed
Public 223 48.4 37.0 57.1
Private, for profit 39 47.5 32.0 58.0
Private, not for profit 14 45.9 34.0 70.8
% Patients with Injection Prescribed
Public 173 20.0 10.0 32.7
Private, for profit 34 19.4 7.0 38.0
Private, not for profit 11 37.0 19.0 63.1
% Treated According to Clinical Guidelines
Public 146 39.3 21.5 59.0
Private, for profit 12 27.5 14.0 37.5
Private, not for profit 2 14.7 11.3 18.1
Average Number of Medicines per Patient
Public 236 2.4 2.0 2.9
Private, for profit 51 3.0 2.4 3.7
Private, not for profit 14 3.0 2.4 3.3
Figure 4.6: WHOINRUD prescribing indicators by health facility ownership (prescribing by 
physicians, nurses, paramedics)
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% Prescribed Medicines Dispensed
1982-1991 7 81.0 57.5 83.3
1992-1994 17 84.5 77.2 90.0
1995-1997 24 81.2 65.8 88.3
1998-2000 32 81.7 70.3 90.0
2001-2003 38 87.0 76.9 98.0
2004-2006 10 92.4 85.5 97.1
% Medicines Adequately Labeled
1982-1991 1 44.0 44.0 44.0
1992-1994 11 49.0 12.0 82.0
1995-1997 17 44.0 19.0 59.5
1998-2000 15 49.4 1.1 91.4
2001-2003 30 47.6 5.0 82.6
2004-2006 10 79.0 64.6 100.0
% Patients Given Dosage Instructions
1982-1991 3 10.0 0.0 15.0
1992-1994 21 53.0 26.0 64.0
1995-1997 28 45.1 26.5 64.5
1998-2000 19 41.0 20.0 60.0
2001-2003 25 47.0 37.0 74.0
2004-2006 7 57.3 49.0 85.0
% Patients with Knowledge of Correct Dose
1982-1991 5 55.0 27.0 56.0
1992-1994 34 57.5 35.0 77.0
1995-1997 34 67.5 50.0 77.0
1998-2000 29 58.0 46.0 65.0
2001-2003 58 68.8 54.4 80.4
2004-2006 20 72.5 56.5 80.8
Average Consultation Time (minutes)
1982-1991 4 2.8 1.7 3.3
1992-1994 22 3.9 2.9 6.3
1995-1997 19 5.5 4.0 6.0
1998-2000 13 4.3 3.6 6.7
2001-2003 11 4.8 3.5 7.8
2004-2006 5 5.6 4.5 6.2
Average Dispensing Time (seconds)
1982-1991 3 86.0 23.0 178.0
1992-1994 15 77.8 14.0 125.0
1995-1997 14 90.4 30.1 130.0
1998-2000 9 47.2 31.0 123.0
2001-2003 6 79.0 25.4 149.0
2004-2006 3 71.3 46.3 176.0
Figure 5.1: WHO/INRUD patient care indicators, by time period
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% Prescribed Medicines Dispensed
Sub-Saharan Africa 60 86.0 76.9 90.0
Latin America and Caribbean 13 69.4 65.5 84.3
Middle East and Central Asia 11 96.8 81.8 98.0
East Asia and Pacific 14 100.0 87.0 100.0
South Asia 30 80.8 70.2 88.0
% Medicines Adequately Labeled
Sub-Saharan Africa 34 49.3 20.2 69.5
Latin America and Caribbean 5 49.0 24.0 74.5
Middle East and Central Asia 9 84.0 65.2 100.0
East Asia and Pacific 16 68.5 51.1 99.5
South Asia 20 1.1 0.0 28.5
% Patients Given Dosage Instructions
Sub-Saharan Africa 49 46.0 32.0 60.2
Latin America and Caribbean 16 36.5 22.3 71.2
Middle East and Central Asia 10 53.5 24.0 61.0
East Asia and Pacific 18 53.5 40.6 67.0
South Asia 10 44.0 31.1 82.0
% Patients with Knowledge of Correct Dose
Sub-Saharan Africa 78 68.5 46.0 80.0
Latin America and Caribbean 21 64.0 55.0 88.5
Middle East and Central Asia 18 63.1 60.0 79.2
East Asia and Pacific 29 74.0 50.0 82.0
South Asia 34 56.1 47.6 66.0
Average Consultation Time (minutes)
Sub-Saharan Africa 33 5.1 3.8 6.1
Latin America and Caribbean 5 10.0 6.7 14.0
Middle East and Central Asia 7 3.9 3.8 5.6
East Asia and Pacific 7 4.4 3.0 7.4
South Asia 22 3.5 2.0 4.8
Average Dispensing Time (seconds)
Sub-Saharan Africa 25 84.0 37.0 132.0
Latin America and Caribbean 1 17.0 17.0 17.0
Middle East and Central Asia 5 30.1 29.7 102.0
East Asia and Pacific 7 36.5 8.0 129.5
South Asia 12 82.3 37.5 136.0










% Prescribed Medicines Dispensed
Low Income 86 83.3 73.0 89.9
Lower-Middle Income 26 86.4 71.1 95.6
Upper-Middle & High Income 16 88.3 68.4 97.5
% Patients Given Dosage Instructions
Low Income 66 46.4 32.0 60.0
Lower-Middle Income 29 48.0 25.0 68.0
Upper-Middle & High Income 8 69.5 19.8 74.5
% Patients with Knowledge of Correct Dose
Low Income 112 61.4 47.3 76.3
Lower-Middle Income 45 73.7 50.0 86.6
Upper-Middle & High Income 23 66.0 61.4 80.0
Average Consultation Time (minutes)
Low Income 55 4.4 2.9 6.0
Lower-Middle Income 11 5.6 3.9 7.8
Upper-Middle & High Income 8 5.6 4.0 8.3
Average Dispensing Time (seconds)
Low Income 36 81.3 34.0 140.5
Lower-Middle Income 9 51.0 28.8 129.5
Upper-Middle & High Income 5 29.7 17.0 30.1
Figure 5.3: WHO/INRUD patient care indicators, by World Bank income level
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% Prescribed Medicines Dispensed
Public 103 85.0 73.0 94.0
Private, for profit 13 75.8 72.5 85.0
Private, not for profit 7 94.3 88.0 98.0
% Medicines Adequately Labeled
Public 69 48.0 7.0 84.0
Private, for profit 6 61.4 49.4 82.0
Private, not for profit 6 56.1 6.7 87.6
% Patients Given Dosage Instructions
Public 86 47.5 29.0 68.0
Private, for profit 10 45.8 40.6 60.0
Private, not for profit 0 . . .
% Patients with Knowledge of Correct Dose
Public 159 62.8 47.6 78.0
Private, for profit 6 83.5 76.0 94.0
Private, not for profit 6 87.8 84.9 92.0
Average Consultation Time (minutes)
Public 51 4.3 2.9 6.3
Private, for profit 10 6.4 5.0 8.7
Private, not for profit 6 5.2 3.7 6.1
Average Dispensing Time (seconds)
Public 36 77.9 29.3 127.3
Private, for profit 4 82.5 43.8 171.0
Private, not for profit 5 39.9 18.1 186.0










% Key Medicines Available in Facility
1982-1991 8 68.5 55.6 76.0
1992-1994 26 76.5 70.0 85.7
1995-1997 24 81.5 59.9 90.5
1998-2000 34 70.0 58.0 84.6
2001-2003 68 80.0 68.5 89.5
2004-2006 22 82.5 80.0 89.0
Availability of Clinical Guidelines
1982-1991 0 . . .
1992-1994 9 65.8 38.0 71.9
1995-1997 11 61.0 22.2 77.0
1998-2000 14 47.0 9.0 61.0
2001-2003 37 66.5 34.0 91.0
2004-2006 15 51.0 40.0 75.0
Availability of EML or Formulary
1982-1991 1 16.0 16.0 16.0
1992-1994 9 80.0 17.5 87.5
1995-1997 8 60.5 30.6 77.5
1998-2000 10 34.8 7.7 81.0
2001-2003 26 42.7 10.0 90.0
2004-2006 7 67.0 37.0 85.0
Figure 5.5: WHO/INRUD health facility indicators, by time period
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% Key Medicines Available in Facility
Sub-Saharan Africa 85 81.5 70.0 89.0
Latin America and Caribbean 29 66.9 57.1 79.5
Middle East and Central Asia 11 91.5 55.2 97.0
East Asia and Pacific 26 80.0 64.0 86.7
South Asia 31 81.1 69.9 88.1
Availability of Clinical Guidelines
Sub-Saharan Africa 46 55.3 34.0 79.5
Latin America and Caribbean 13 46.0 17.4 70.0
Middle East and Central Asia 8 84.0 3.5 93.0
East Asia and Pacific 15 70.0 49.0 94.0
South Asia 4 26.7 1.2 51.5
Availability of EML or Formulary
Sub-Saharan Africa 28 51.5 17.3 82.9
Latin America and Caribbean 10 58.5 39.3 87.5
Middle East and Central Asia 6 59.5 44.0 96.0
East Asia and Pacific 8 80.0 36.3 100.0
South Asia 9 4.8 0.0 16.0










% Key Medicines Available in Facility
Low Income 118 80.0 68.4 86.7
Lower-Middle Income 43 79.5 60.0 91.0
Upper-Middle & High Income 21 83.0 58.0 93.3
Availability of Clinical Guidelines
Low Income 48 50.5 25.0 71.0
Lower-Middle Income 29 65.8 39.3 85.0
Upper-Middle & High Income 9 83.0 62.0 96.0
Availability of EML or Formulary
Low Income 39 45.0 10.0 85.0
Lower-Middle Income 16 50.5 22.9 84.5
Upper-Middle & High Income 6 64.5 59.0 96.0










% of Key Medicines Available in Facility
Public 135 80.0 64.9 86.7
Private, for profit 33 80.0 69.4 86.7
Private, not for profit 8 88.8 64.2 91.4
Availability of Clinical Guidelines
Public 78 60.5 38.0 83.0
Private, for profit 4 5.7 2.9 16.5
Private, not for profit 2 19.2 17.4 21.0
Availability of EML/Formulary
Public 52 51.5 10.6 88.2
Private, for profit 3 41.4 11.9 63.0
Private, not for profit 3 57.0 8.7 100.0
Figure 5.8: WHO/INRUD health facility indicators, by facility ownership
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% Cases of URTI Treated with Antibiotics
1982-1991 11 43.4 26.0 76.0
1992-1994 18 54.2 31.0 83.0
1995-1997 26 40.4 25.0 66.0
1998-2000 24 50.9 24.2 71.1
2001-2003 35 68.8 52.0 85.2
2004-2006 12 70.5 48.0 83.5
% Pneumonia Cases Treated with Recommended Antibiotics
1982-1991 5 80.0 66.7 80.0
1992-1994 15 69.0 42.2 82.5
1995-1997 16 60.5 46.5 78.0
1998-2000 25 58.1 42.0 79.0
2001-2003 39 53.7 28.0 75.0
2004-2006 16 76.5 45.5 92.2
% Treated According to Clinical Guidelines
1982-1991 3 52.7 41.0 58.8
1992-1994 8 42.1 29.0 58.2
1995-1997 11 38.2 29.0 43.3
1998-2000 13 35.0 25.2 50.0
2001-2003 22 43.0 18.1 62.0
2004-2006 8 34.9 22.0 51.5
% ARI Cases Treated with Cough Syrups
1982-1991 7 54.0 24.8 96.4
1992-1994 4 37.9 23.8 51.2
1995-1997 6 61.2 45.0 63.0
1998-2000 7 49.9 16.5 61.5
2001-2003 12 34.3 12.8 46.5
2004-2006 0 . . .










% Cases of URTI Treated with Antibiotics
1982-1991 8 42.9 28.0 75.0
1992-1994 14 36.9 18.0 70.0
1995-1997 23 39.6 24.0 65.0
1998-2000 16 42.5 21.5 61.0
2001-2003 12 58.7 29.0 74.9
2004-2006 5 71.0 65.1 71.5
% Pneumonia Cases Treated with Recommended Antibiotics
1982-1991 5 80.0 66.7 80.0
1992-1994 15 69.0 42.2 82.5
1995-1997 15 63.0 50.0 81.0
1998-2000 22 55.4 40.0 66.0
2001-2003 29 50.0 25.3 73.0
2004-2006 10 64.5 27.0 77.0
% Treated According to Clinical Guidelines
1982-1991 2 55.8 52.7 58.8
1992-1994 8 42.1 29.0 58.2
1995-1997 8 38.7 29.6 43.2
1998-2000 11 35.0 25.2 53.0
2001-2003 19 51.4 18.1 71.0
2004-2006 8 34.9 22.0 51.5
% ARI Cases Treated with Cough Syrups
1982-1991 4 60.6 24.1 97.6
1992-1994 3 34.5 13.0 41.2
1995-1997 4 62.7 53.7 81.5
1998-2000 3 51.0 49.9 86.6
2001-2003 5 10.0 6.2 30.0
2004-2006 0 . . .
Figure 6.2: ARI treatment indicators over time, including only studies of medicine use in children 
< 5 years with ARI
 
Medicines use in primary care, 1990-2006 








% Cases of URTI Treated with Antibiotics
Sub-Saharan Africa 36 73.0 51.1 89.8
Latin America and Caribbean 20 54.7 21.2 73.9
Middle East and Central Asia 24 58.8 41.5 69.5
East Asia and Pacific 35 39.8 25.0 65.0
South Asia 11 53.0 18.0 75.7
% Pneumonia Cases Treated with Recommended Antibiotics
Sub-Saharan Africa 50 58.5 34.0 78.0
Latin America and Caribbean 21 70.0 45.0 87.5
Middle East and Central Asia 17 66.7 58.1 75.0
East Asia and Pacific 16 74.3 64.5 91.0
South Asia 12 33.8 11.9 61.0
% Treated According to Clinical Guidelines
Sub-Saharan Africa 27 43.0 22.5 60.0
Latin America and Caribbean 11 51.4 39.2 66.0
Middle East and Central Asia 8 40.9 29.2 55.8
East Asia and Pacific 12 35.1 18.3 43.1
South Asia 7 16.0 11.1 41.0
% ARI Cases Treated with Cough Syrups
Sub-Saharan Africa 11 34.5 15.6 49.9
Latin America and Caribbean 4 51.5 41.5 63.8
Middle East and Central Asia 6 58.2 45.0 96.4
East Asia and Pacific 8 53.4 28.9 63.5
South Asia 7 26.4 13.0 51.0











% Cases of URTI Treated with Antibiotics
Low Income 59 63 31 81.2
Low Middle Income 44 54.65 25.51 65.28
Upper Middle & High Income 23 59 27.7 80.3
% Pneumonia Cases Treated with Recommended Antibiotics
Low Income 65 52.85 27 76
Low Middle Income 32 73.8 59.15 81.65
Upper Middle & High Income 19 75 58.12 89
% Treated According to Clinical Guidelines
Low Income  34.9 18.12 46.3
Low Middle Income 19 42.9 29.9 58.8
Upper Middle & High Income 9 62 51.4 67.5
% ARI Cases Treated with Cough Syrups
Low Income 19 30 15.6 47.8
Low Middle Income 9 62.3 40 63.97
Upper Middle & High Income 8 60.6 49.5 64.5
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% Cases of URTI Treated with Antibiotics
MD 39 67.9 42.4 82.4
Paramedic or Nurse 62 59.0 29.0 77.0
Pharmacy Staff, Other, or Unspecified 26 47.7 26.0 62.0
% Pneumonia Cases Treated with Recommended Antibiotics
MD 19 72.0 53.3 83.0
Paramedic or Nurse 86 63.0 42.1 78.4
Pharmacy Staff, Other, or Unspecified 12 44.0 21.8 71.4
% Treated According to Clinical Guidelines
MD 12 45.1 35.1 63.2
Paramedic or Nurse 51 39.3 22.9 57.0
Pharmacy Staff, Other, or Unspecified 2 8.3 3.0 13.7
% ARI Cases Treated with Cough Syrups
MD 17 45.2 35.6 64.0
Paramedic or Nurse 10 33.7 22.8 62.3
Pharmacy Staff, Other, or Unspecified 9 40.0 24.8 49.9











% Cases of URTI Treated with Antibiotics
Public 86 58.8 29.9 76.9
Private, for profit 10 76.6 68.8 83.0
Private, not for profit 0 . . .
% Pneumonia Cases Treated with Recommended Antibiotics
Public 95 66.0 43.0 81.0
Private, for profit 6 67.4 49.7 91.5
Private, not for profit 0 . . .
% Treated According to Clinical Guidelines
Public 58 39.3 27.8 58.0
Private, for profit 2 37.9 23.0 52.7
Private, not for profit 1 18.1 18.1 18.1
% ARI Cases Treated with Cough Syrups
Public 16 45.1 27.9 62.7
Private, for profit 5 41.2 13.0 80.4
Private, not for profit 2 19.1 8.2 30.0
Figure 6.6: ARI treatment indicators for all studies of medicine use in ARI, by health care facility 










% Key Medicines Available in Facility
Sub-Saharan Africa 24 76.1 64.5 83.0
Latin America and Caribbean 9 60.7 58.0 62.8
Middle East and Central Asia 2 62.5 28.0 97.0
East Asia and Pacific 3 86.0 80.0 89.0
South Asia 4 62.0 44.2 70.0
Figure 6.7: Percentage of key medicines available in health facilities for ARI treatment, by World 
Bank region
 
Medicines use in primary care, 1990-2006 








% Diarrhoea Cases Treated with Antibiotics
1982-1991 24 47.9 29.7 79.3
1992-1994 36 38.5 19.6 56.2
1995-1997 23 33.3 11.0 50.5
1998-2000 13 35.7 19.5 50.0
2001-2003 27 62.0 44.4 73.1
2004-2006 11 46.0 24.3 60.0
% Diarrhoea Cases Treated with Antidiarrhoeals
1982-1991 14 20.2 18.0 51.0
1992-1994 26 17.0 10.0 46.2
1995-1997 13 14.0 0.0 25.0
1998-2000 10 8.7 0.8 36.4
2001-2003 21 10.0 5.0 25.7
2004-2006 7 5.0 0.0 20.1
% Diarrhoea Cases Treated with ORT
1982-1991 27 35.0 13.9 60.0
1992-1994 38 52.9 30.1 80.0
1995-1997 24 45.6 29.5 61.0
1998-2000 21 43.0 20.0 78.1
2001-2003 36 52.0 36.7 74.9
2004-2006 13 77.5 60.0 80.6
% Treated According to Clinical Guidelines
1982-1991 2 36.6 32.2 41.0
1992-1994 31 25.0 8.3 46.3
1995-1997 15 24.0 7.6 47.0
1998-2000 10 39.5 27.8 53.0
2001-2003 13 42.9 17.1 60.5
2004-2006 7 39.3 21.0 57.0











% Diarrhoea Cases Treated with Antibiotics
1982-1991 16 53.8 29.7 84.8
1992-1994 28 27.5 18.6 52.3
1995-1997 18 22.0 10.0 48.0
1998-2000 9 34.3 19.0 50.0
2001-2003 9 56.5 26.0 66.0
2004-2006 4 41.5 19.8 60.6
% Diarrhoea Cases Treated with Antidiarrhoeals
1982-1991 11 20.0 17.5 51.0
1992-1994 20 15.0 9.7 35.8
1995-1997 9 5.0 0.0 17.3
1998-2000 6 17.7 1.0 36.4
2001-2003 7 10.0 4.5 32.0
% Diarrhoea Cases Treated with ORT
1982-1991 21 27.6 13.6 60.0
1992-1994 29 52.8 32.0 81.4
1995-1997 16 48.5 22.3 61.5
1998-2000 15 23.1 10.0 62.0
2001-2003 19 50.0 20.0 60.0
2004-2006 6 69.5 40.0 80.6
% Treated According to Clinical Guidelines
1982-1991 0 . . .
1992-1994 29 25.0 13.0 46.2
1995-1997 13 20.0 7.6 35.7
1998-2000 9 44.0 27.8 53.0
2001-2003 13 42.9 17.1 60.5
2004-2006 7 39.3 21.0 57.0
Figure 7.2: Diarrhoea treatment indicators over time, including only studies of medicine use in 
children <5 years with acute diarrhoea
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% Diarrhoea Cases Treated with Antibiotics
Sub-Saharan Africa 45 42.0 20.2 63.0
Latin America and Caribbean 30 40.0 21.7 57.5
Middle East and Central Asia 9 22.0 8.0 31.0
East Asia and Pacific 22 55.9 46.0 81.3
South Asia 28 50.7 30.8 75.5
% Diarrhoea Cases Treated with Antidiarrhoeals
Sub-Saharan Africa 36 10.0 3.7 36.0
Latin America and Caribbean 17 17.5 9.5 26.3
Middle East and Central Asia 6 15.0 6.5 19.0
East Asia and Pacific 18 16.6 10.0 27.7
South Asia 14 19.8 10.0 38.6
% Diarrhoea Cases Treated with ORT
Sub-Saharan Africa 64 55.0 30.1 77.8
Latin America and Caribbean 25 43.0 10.0 60.0
Middle East and Central Asia 10 42.9 13.6 57.0
East Asia and Pacific 27 60.0 29.4 77.0
South Asia 33 53.1 30.4 80.0
% Treated According to Clinical Guidelines
Sub-Saharan Africa 32 43.5 19.5 57.5
Latin America and Caribbean 17 39.3 23.0 53.0
Middle East and Central Asia 8 26.4 9.0 42.9
East Asia and Pacific 11 25.0 15.0 42.9
South Asia 10 14.8 8.3 33.0
Figure 7.3: Diarrhoea treatment indicators including all studies of medicine use for acute 










% Diarrhoea Cases Treated with Antibiotics
Low Income 77 49.0 23.0 65.5
Lower-Middle Income 40 50.0 24.5 69.7
Upper-Middle & High Income 17 24.3 19.5 37.0
% Diarrhoea Cases Treated with Antidiarrhoeals
Low Income 50 10.0 2.8 37.0
Lower-Middle Income 32 19.0 14.4 33.1
Upper-Middle & High Income 9 12.7 9.5 15.4
% Diarrhoea Cases Treated with ORT
Low Income 100 52.8 28.4 77.5
Lower-Middle Income 40 45.0 16.8 63.5
Upper-Middle & High Income 19 52.8 29.4 90.0
% Treated According to Clinical Guidelines
Low Income 43 35.0 17.0 51.0
Lower-Middle Income 22 26.0 15.0 44.0
Upper-Middle & High Income 13 37.0 23.0 65.2
Figure 7.4: Diarrhoea treatment indicators including all studies of medicine use for acute 




Medicines use in primary care, 1990-2006 








% Diarrhoea Cases Treated with Antibiotics
MD 34 60.0 37.0 82.3
Paramedic or Nurse 69 44.0 19.0 62.0
Pharmacy Staff, Other, or Unspecified 33 35.4 23.0 53.0
% Diarrhoea Cases Treated with Antidiarrhoeals
MD 24 18.2 10.5 22.5
Paramedic or Nurse 43 7.4 1.0 25.7
Pharmacy Staff, Other, or Unspecified 27 32.0 19.1 57.0
% Diarrhoea Cases Treated with ORT
MD 33 56.0 44.0 80.0
Paramedic or Nurse 77 63.0 44.8 80.0
Pharmacy Staff, Other, or Unspecified 52 21.5 12.1 45.4
% Treated According to Clinical Guidelines
MD 14 25.0 15.0 44.2
Paramedic or Nurse 61 37.0 17.0 51.0
Pharmacy Staff, Other, or Unspecified 3 25.0 1.7 29.5
Figure 7.5: Diarrhoea treatment indicators including all studies of medicine use for acute 










% Diarrhoea Cases Treated with Antibiotics
Public 87 49.0 20.2 64.0
Private, for profit 9 73.1 64.3 96.0
Private, not for profit 0 . . .
% Diarrhoea Cases Treated with Antidiarrhoeals
Public 54 10.0 4.7 19.0
Private, for profit 5 38.6 25.0 45.0
Private, not for profit 0 . . .
% Diarrhoea Cases Treated with ORT
Public 90 62.5 45.1 81.4
Private, for profit 10 40.7 33.3 57.0
Private, not for profit 0 . . .
% Treated According to Clinical Guidelines
Public 70 34.0 15.0 50.0
Private, for profit 2 23.0 23.0 23.0
Private, not for profit 0 . . .
Figure 7.6: Diarrhoea treatment indicators for all studies of medicine use for acute diarrhoea, by 










% Key Medicines Available in Facility
Sub-Saharan Africa 21 76.0 65.0 82.0
Latin America and Caribbean 7 58.0 55.0 61.0
Middle East and Central Asia 2 62.5 28.0 97.0
East Asia and Pacific 2 84.5 80.0 89.0
South Asia 4 62.0 44.2 70.0











% Malaria Cases Treated with Recommended Antimalarials (All Ages)
1982-1991 4 72.2 57.7 90.4
1992-1994 6 70.6 56.0 90.6
1995-1997 5 47.0 21.5 68.0
1998-2000 21 60.6 27.0 75.0
2001-2003 27 56.5 18.7 71.0
2004-2006 9 51.0 37.0 68.0
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% Malaria Cases Treated with Recommended Antimalarials (Children < 5 Years)
1982-1994 4 70.0 55.0 89.5
1995-2000 23 47.0 21.5 74.8
2001-2006 29 56.5 29.0 69.2
% Malaria Cases Treated with Recommended Antimalarials (Adults)
1982-1994 6 72.2 57.2 90.6
1995-2000 3 71.5 60.6 89.9
2001-2006 7 55.0 16.0 94.9
Figure 8.2: Prescribing of recommended antimalarial treatment over time, comparing studies that 










% Antibiotics Prescribed in Underdosage
1982-1994 6 66.0 40.0 72.0
1995-2000 14 54.7 38.5 73.0
2001-2006 8 54.9 31.1 66.0
% Patients Prescribed Antibiotics Inappropriately
1982-1994 97 42.0 21.0 70.0
1995-2000 103 39.6 21.0 61.9
2001-2006 121 55.4 27.7 72.9










% Antibiotics Prescribed in Underdosage
Sub-Saharan Africa 11 54.8 38.5 73.0
Latin America and Caribbean 4 67.0 60.5 76.8
Middle East and Central Asia 3 29.7 22.0 67.0
East Asia and Pacific 4 61.4 51.4 80.0
South Asia 6 38.1 22.8 55.0
% Patients Prescribed Antibiotics Inappropriately
Sub-Saharan Africa 104 47.3 21.5 71.5
Latin America and Caribbean 67 37.0 19.0 59.0
Middle East and Central Asia 39 43.7 22.0 65.1
East Asia and Pacific 64 49.8 32.0 68.1
South Asia 47 52.8 29.0 73.1










% Antibiotics Prescribed in Underdosage
Low Income 20 53.7 37.4 71.5
Lower-Middle Income 3 81.7 59.0 90.0
Upper-Middle & High Income 5 62.0 29.7 67.0
% Patients Prescribed Antibiotics Inappropriately
Low Income 166 49.3 25.0 70.3
Lower-Middle Income 98 47.0 24.0 65.1
Upper-Middle & High Income 57 36.8 19.5 64.9










% Antibiotics Prescribed in Underdosage
MD 10 55.9 29.7 62.0
Paramedic or Nurse 12 45.6 29.3 62.5
Pharmacy Staff, Other, or Unspecified 8 72.5 50.0 90.0
% Patients Prescribed Antibiotics Inappropriately
MD 91 59.3 36.8 79.0
Paramedic or Nurse 174 41.4 20.0 65.2
Pharmacy Staff, Other, or Unspecified 60 40.5 23.7 56.3
Figure 9.4: Inappropriate prescribing of antibiotics, by type of prescriber
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% Patients Prescribed Antibiotics Inappropriately
Public 228 44.7 22.0 66.2
Private, for profit 22 72.4 64.3 83.0
Private, not for profit 0 . . .
% Antibiotics Prescribed in Underdosage
Public 13 52.7 26.0 59.0
Private, for profit 6 55.9 30.0 73.0
Private, not for profit 0 . . .
Figure 9.5: Inappropriate prescribing of antibiotics, by health care facility ownership (prescribing 










% Medicines from EML or Formulary
Africa 67 87.8 69.0 94.0
Americas 16 71.4 43.0 85.3
Eastern Mediterranean 13 82.5 50.0 95.0
Europe 4 55.1 43.8 69.2
South-East Asia 47 81.0 48.8 89.4
Western Pacific 15 78.1 58.6 86.6
% Medicines Prescribed by Generic Name
Africa 89 60.0 36.1 80.0
Americas 14 67.3 52.0 74.0
Eastern Mediterranean 16 27.7 12.5 81.3
Europe 14 48.9 34.0 63.0
South-East Asia 50 44.0 17.1 69.8
Western Pacific 9 78.0 64.5 88.1
% Patients with an Antibiotic Prescribed
Africa 135 47.0 38.0 55.5
Americas 28 39.3 30.9 65.6
Eastern Mediterranean 39 53.2 40.5 62.3
Europe 16 33.5 24.3 55.8
South-East Asia 94 46.3 36.0 55.0
Western Pacific 30 45.0 27.4 60.0
% Patients with Injection Prescribed
Africa 124 27.5 17.6 38.0
Americas 14 13.2 10.5 24.0
Eastern Mediterranean 34 20.1 8.0 47.2
Europe 14 17.2 13.0 30.0
South-East Asia 61 9.1 5.0 17.0
Western Pacific 21 23.2 7.0 35.5
% Treated According to Clinical Guidelines
Africa 106 43.2 19.0 62.0
Americas 28 39.3 21.5 52.2
Eastern Mediterranean 16 36.8 23.0 46.7
Europe 4 37.2 17.8 39.7
South-East Asia 37 28.7 15.0 42.8
Western Pacific 14 28.4 12.4 42.9
Average Number of Medicines per Patient
Africa 145 2.6 2.1 3.2
Americas 32 1.8 1.3 2.3
Eastern Mediterranean 41 2.7 2.3 3.6
Europe 22 2.5 1.8 2.9
South-East Asia 105 2.5 2.1 2.9
Western Pacific 25 2.6 2.2 3.7
Annex Figure 2.1: WHO/INRUD prescribing indicators by WHO region
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% Prescribed Medicines Dispensed
Africa 60 86.0 76.9 90.0
Americas 13 69.4 65.5 84.3
Eastern Mediterranean 12 95.0 80.4 97.0
Europe 3 69.6 61.0 98.0
South-East Asia 27 81.2 66.0 90.3
Western Pacific 13 100.0 87.0 100.0
% Medicines Adequately Labeled
Africa 34 49.3 20.2 69.5
Americas 5 49.0 24.0 74.5
Eastern Mediterranean 13 38.0 12.6 84.0
Europe 1 100.0 100.0 100.0
South-East Asia 19 0.0 0.0 70.0
Western Pacific 12 81.9 51.1 100.0
% Patients Given Dosage Instructions
Africa 49 46.0 32.0 60.2
Americas 16 36.5 22.3 71.2
Eastern Mediterranean 9 51.0 31.3 61.0
Europe 3 56.0 14.0 93.0
South-East Asia 14 41.3 15.0 64.0
Western Pacific 12 55.0 49.0 67.0
% Patients with Knowledge of Correct Dose
Africa 78 68.5 46.0 80.0
Americas 21 64.0 55.0 88.5
Eastern Mediterranean 18 61.2 56.2 75.5
Europe 4 77.0 49.5 90.5
South-East Asia 41 57.7 47.6 75.0
Western Pacific 18 73.5 55.0 88.3
Average Consultation Time (minutes)
Africa 33 5.1 3.8 6.1
Americas 5 10.0 6.7 14.0
Eastern Mediterranean 12 4.0 3.2 5.2
Europe 1 2.0 2.0 2.0
South-East Asia 20 3.5 1.9 4.8
Western Pacific 3 7.4 4.4 7.8
Average Dispensing Time (seconds)
Africa 25 84.0 37.0 132.0
Americas 1 17.0 17.0 17.0
Eastern Mediterranean 7 102.0 30.1 149.0
Europe 1 29.7 29.7 29.7
South-East Asia 13 51.0 31.0 102.0
Western Pacific 3 14.8 8.0 235.0










% Key Medicines Available in Facility
Africa 85 81.5 70.0 89.0
Americas 29 66.9 57.1 79.5
Eastern Mediterranean 9 92.0 83.0 97.0
Europe 3 30.0 28.0 64.9
South-East Asia 33 81.1 69.9 89.4
Western Pacific 23 80.0 64.0 86.7
Availability of Clinical Guidelines
Africa 46 55.3 34.0 79.5
Americas 13 46.0 17.4 70.0
Eastern Mediterranean 7 91.0 52.0 94.0
Europe 2 3.5 0.0 7.0
South-East Asia 9 51.0 38.0 65.8
Western Pacific 9 83.0 67.0 96.0
Availability of EML or Formulary
Africa 28 51.5 17.3 82.9
Americas 10 58.5 39.3 87.5
Eastern Mediterranean 6 59.5 44.0 93.0
Europe 1 100.0 100.0 100.0
South-East Asia 9 4.8 0.0 16.0
Western Pacific 7 80.0 12.5 100.0
Annex Figure 2.3: WHO/INRUD health facility indicators by WHO region
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Annex Figure 2.4: ARI treatment indicators in studies that included patients of all ages by 
WHO region 





% Cases of URTI Treated with Antibiotics 
  Africa  36.0 73.0 51.1 89.8 
  Americas  20.0 54.7 21.2 73.9 
  Eastern Mediterranean  11.0 53.0 43.4 67.9 
  Europe  15.0 62.4 24.0 73.0 
  South-East Asia  18.0 50.2 26.0 70.0 
  Western Pacific   26.0 37.4 24.0 64.9 
% Pneumonia Cases Treated with Recommended Antibiotics 
  Africa  50.0 58.5 34.0 78.0 
  Americas  21.0 70.0 45.0 87.5 
  Eastern Mediterranean  11.0 71.1 60.4 75.0 
  Europe  8.0 60.6 33.5 74.5 
  South-East Asia  14.0 52.5 12.5 76.4 
  Western Pacific   12.0 74.3 64.5 91.0 
% Treated According to Clinical Guidelines 
  Africa  27.0 43.0 22.5 60.0 
  Americas  11.0 51.4 39.2 66.0 
  Eastern Mediterranean  8.0 40.4 29.2 55.8 
  Europe  1.0 38.9 38.9 38.9 
  South-East Asia  10.0 33.1 12.5 43.3 
  Western Pacific   8.0 28.4 13.0 40.6 
% ARI Cases Treated with Cough Syrups 
  Africa  11.0 34.5 15.6 49.9 
  Americas  4.0 51.5 41.5 63.8 
  Eastern Mediterranean  8.0 49.5 27.1 79.4 
  Europe  0.0 . . . 
  South-East Asia  8.0 35.8 23.8 57.0 
  Western Pacific  5.0 61.5 32.9 64.0 
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% Diarrhoea Cases Treated with Antibiotics
Africa 45 42.0 20.2 63.0
Americas 30 40.0 21.7 57.5
Eastern Mediterranean 14 24.6 17.4 40.6
Europe 1 31.0 31.0 31.0
South-East Asia 34 53.8 35.7 83.0
Western Pacific 10 50.0 33.3 60.0
% Diarrhoea Cases Treated with Antidiarrhoeals
Africa 36 10.0 3.7 36.0
Americas 17 17.5 9.5 26.3
Eastern Mediterranean 10 19.6 18.7 38.6
Europe 1 11.0 11.0 11.0
South-East Asia 21 18.4 11.9 40.0
Western Pacific 6 7.5 0.0 13.0
% Diarrhoea Cases Treated with ORT
Africa 64 55.0 30.1 77.8
Americas 25 43.0 10.0 60.0
Eastern Mediterranean 17 45.1 33.3 57.0
Europe 1 0.0 0.0 0.0
South-East Asia 41 54.7 30.1 80.0
Western Pacific 11 48.3 28.6 82.0
% Treated According to Clinical Guidelines
Africa 32 43.5 19.5 57.5
Americas 17 39.3 23.0 53.0
Eastern Mediterranean 6 26.4 11.0 47.0
Europe 2 19.4 0.0 38.9
South-East Asia 16 20.0 9.7 31.3
Western Pacific 5 37.0 22.9 42.9











% Antibiotics Prescribed in Underdosage
Africa 11 54.8 38.5 73.0
Americas 4 67.0 60.5 76.8
Eastern Mediterranean 3 36.2 22.0 67.0
Europe 1 29.7 29.7 29.7
South-East Asia 5 40.0 22.8 55.0
Western Pacific 4 61.4 51.4 80.0
% Patients Prescribed Antibiotics Inappropriately
Africa 104 47.3 21.5 71.5
Americas 67 37.0 19.0 59.0
Eastern Mediterranean 29 40.6 22.0 61.9
Europe 18 58.8 22.0 71.0
South-East Asia 61 54.0 34.0 74.0
Western Pacific 42 41.7 27.7 60.0
Annex Figure 2.6: Inappropriate antibiotic prescribing by WHO region
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ANNEX 2: RESULTS BY WHO REGION 
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Annex Figure 2.4: ARI treatment indicators in studies that included patients  
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Annex Figure 2.5: Diarrhoea treatment indicators in studies that included patients  
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ANNEX 3: WHO INDICATORS DATABASE MANUAL 
Database on drug*  use in developing and transitional countries — 
Manual, WHO/EMP, Geneva, 2007 
Authors: Kathleen Holloway and Verica Ivanovska 
INTRODUCTION 
Entering articles or reports in the database 
One of the objectives of the drug use database is to be able to monitor how much work has 
been done in this area over time. Therefore a very important principle underlying data‐entry 









entered  into  the database  for  that  article  or  report. However,  this may  not  apply  in  two 
circumstances.  Firstly,  studies  or  surveys  may  be  described  in  more  than  one  report  or 
article ‐ in which case up to three references (of articles or reports) may be entered into the 
database to cite the one study or survey. Secondly, articles and reports may describe more 
than one  study or  survey  ‐  in which  case  each described  study or  survey  is  entered  as  a 
separate record, i.e. one article/report may be divided into two or more records. Division of 
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Different time periods 
If no interventions are described in association with the drug use data, then surveys done at 
different  time  periods  on  the  same  drug  users  are  entered  in  different  records.  If 
interventions are described in association with the drug use surveys, then the surveys done 
at different time periods on the same drug users in association with the intervention(s) are 
entered  in  the same record. For example,  for a pre‐post study  to evaluate an  intervention, 
the pre‐intervention  and post‐intervention  surveys  should be  entered  in  the  same  record. 
Different  drug  use  surveys  for  different  years  done  not  in  association  with  any 
intervention(s), but described in one report, should be entered as different records. 
Different drug outlet type, outlet ownership, prescriber & dispenser type 
If drug use indicators are described separately for different drug outlet types or ownership 
or  different  prescriber/dispenser  type,  then  the  results  for  each  type  of  facility  or 
prescriber/dispenser should be entered as a separate record.  If  the drug use  indicators are 
described for different types of facility   or prescriber, combined, then only one record may 
be  entered  and  the  appropriate mixed  category  for  outlet  type  or prescriber  type  chosen 
from the menu (see Section 1). 
Different patient type 
If an article/report describes drug use  indicators  separately  for  inpatients and outpatients 
that  are  treated  in  the  same  facilities  and  by  the  same  prescribers,  then  the  results  for 
inpatients  and outpatients  should be  entered  into  the database  as  separate  records.  In  all 
other circumstances studies or surveys will be divided into different records on the basis of 
facility or prescriber type rather than patient type (see Section 1). 
Different patient age 
If  an  article/report  describes  drug  use  separately  for  patients  of  different  ages,  the 
study/survey should be entered into the database as one record. Such a survey should not be 
divided  into  two records merely on  the basis of patient age even  if  this means  that certain 
general drug use  indicators have  to be calculated by averaging across  results  for different 
patient ages. Some articles/reports may describe some drug use  indicators  for all ages and 
some for children < 5 years. In such articles/reports, the age group relating to the majority of 
drug use  indicators should be chosen and notes made  in Sections 3 and 4 about  indicators 
relating to the age group not chosen in Section 1. 
Different diseases 
If  an  article/report  describes  drug  use  for  different  diseases,  the  study/survey  should  be 
entered  into  the  database  as  one  record.  Such  a  survey  should  not  be  divided  into  two 
records merely on the basis of disease even if this means that certain general indicators that 
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are not specific to a disease (e.g. % patients treated  in compliance with standard treatment 
guidelines), have to be calculated by averaging across results for different diseases.  
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Entering a new study or survey 
To  enter  a  new  study,  click  the  cursor  on  the  starred  right‐hand  arrow  at  the  bottom  of 
section one to get a new blank record. 
Survey ID (auto-generated) and country name 
These two boxes (in yellow and above the section menu) are automatically generated once 
one  chooses  a  country  from  the menu  in  the  first  upper  left‐hand  box  in  section  1.  The 
Survey ID number generated should be written on the hard copy of the article in order that 
the record for that article may be easily found in the database. 







In order  to search  for records, put  the cursor  in  the  field  (box) you wish  to search by, e.g. 
country or ID number or year of survey. Then click on the binocular icon in the menu of the 
access software. A ʺFind and replaceʺ box will appear, usually in the ʺFindʺ mode by default. 
If  the box  is  in  the  ʺReplaceʺ mode,  it must be changed  to  the  ʺFindʺ mode by clicking on 
ʺFind  ʺ at  the  top of  the  ʺFind and replaceʺ box. Place  the cursor  in  the  ʺFind whatʺ blank 
space in the box and type in what it is you wish to search for ‐ ID number, country, year of 
survey, etc. The next record with the specification you have searched by will then appear.   
Deleting a record 
Sometimes  a  record must be deleted when  it  is  later  found  that  a  study/survey has been 







complete record (all sections) cannot be deleted  if the cursor  is placed  in any section apart 
from section 1. (Blank outcome field boxes can be deleted in section 4, by clicking on the first 
blank box underneath a filled in box, then going to edit and choosing to delete a record.) 
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Year of publication 
Type  in the year the article or report was published. If the year of publication  is unknown 
every effort should be made to trace the authors to find out the year of publication; lack of 
this  information  casts doubt  on  the  authenticity  and  usefulness  of  the  survey within  the 
database. 
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Study # and Show list of studies 
The  box  ʺstudy  #ʺ  is  designed  to  help  one  keep  track  of  the  number  of  baseline  studies 
already entered for the specified country each year. Before entering a number in the ʺstudy 
#ʺ box for a new record, the data‐entry person should click on box ʺshow list of studiesʺ to 
see  if  there are any other  records already entered  for  that  country with a baseline  survey 
done the same year. If there are no other records entered with a baseline survey for the same 
year as the study being presently entered, then ʺ1ʺ may be entered  in the ʺstudy #ʺ box, as 
this  is  the  first  baseline  survey  in  the  database  for  this  country  in  this  year.  If  there  are 
already studies entered with baseline surveys  for  the same year  in question,  then  the next 
consecutive number should be entered in the ʺstudy #ʺ box. For example, if there are already 
two  studies entered with baseline  surveys  for  the  same year as  the  study being presently 
entered,  then  ʺ3ʺ  should be entered  in  the  ʺstudy #ʺ box as  this  is  the  third  survey  in  the 





and  reopened.  In  such  circumstances  ʺstudy  #ʺ  can  only be  entered  once  the  citation has 
been entered into the citation box and the database closed and opened again. 





Year of post intervention survey 
This box should only be filled in for those studies with an intervention. The final year of any 
data  collection  is  the  year  that  should  be  entered.  Thus  for  studies  with  several  data 
collection  periods  post‐intervention,  it  is  the  year  of  the  final  data  collection  period  that 
should be entered.  
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worker  home  visits  but  it  is  drug  use  in  primary  health‐care  facilities  that  is  actually 
measured  through a prescription survey,  then  the drug outlet  type  is  ʺprimary health‐care 
facilityʺ. If exiting patients are interviewed at health facilities about their drug use practices 
at home for the current illness prior to coming to the health facility then the drug outlet type 
is  ʺhouseholdʺ.    If householders  are  interviewed  about  treatment  received  for  the  current 















mixed  variable  response  can  be  used  e.g.  ʺHospital  and  PHC  facilityʺ.  If  there  is  no 
equivalent mixed  variable  response,  e.g.  shops  and household,  then  the drug  outlet  type 
should be  ʺdonʹt knowʺ  if no particular  facility  type predominates by 80% or more.  If one 
particular facility type predominates by 80% or more, then that facility type should be used 
rather  than  ʺdonʹt  know  ʺ.  In  all  cases,  a  note  should  be  made  in  section  3  of  the  % 
distribution of drug outlet or facility types.  
Drug outlet ownership 
Select the drug outlet ownership from the menu.  
 
Drug outlet ownership refers  to  the distinction between public or private  facilities. Private 







If  outcome  variables  are  reported  for  a  mixture  of  facility  ownership,  then  the  facility 
ownership should be ʺdonʹt knowʺ if no particular type of facility ownership predominates 
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by 80% or more. If one particular type of facility ownership predominates by 80% or more, 





Prescriber  type  (e.g. doctor, paramedic, etc)  refers  to whose prescribing  is measured. This 
may not necessarily be the persons interviewed or observed. For example, if exiting patients 
are  interviewed  at health  facilities  about  their drug use practices  at home  for  the  current 
illness prior to coming to the health facility then the prescriber type is ʺselfʺ.  If householders 
are  interviewed  about  treatment  received  for  the  current  illness  from  the  local  primary 





Prescriber  type  refers  to  the  main  prescriber  in  the  study  irrespective  of  whether  the 
intervention is aimed at that prescriber or whether there are prescribing outcome variables. 







by  interview,  the  prescriber  type  is  often  “don’t  know”  because  people  consult  various 
prescribers; in this case a note of the % of people consulting different prescribers should be 









response  can  be  used  e.g.  ʺMD/paramedic/nurseʺ,  etc.  If  there  is  no  equivalent  mixed 
variable  response,  e.g.  MDs  and  pharmacists,  then  the  prescriber  type  should  be  ʺdonʹt 
knowʺ if no particular prescriber type predominates by 80% or more. If one prescriber type 
does predominate by  80%  or more,  then  that prescriber  type  should  be used  rather  than 
ʺdonʹt knowʺ.  In all cases, a note should be made  in section 3 of  the % distribution of  the 
prescriber types.  
 
In  the  case  of  household  studies/surveys  where  only  mortality  rates  and  no  prescribing 
outcomes are  reported,  the prescriber  type  is usually  ʺdonʹt knowʺ.  In most but not all of 
such mortality studies the interventions target many cadres of health‐care provider and the 
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consumer and it is impossible to say which ʺprescriber typeʺ is responsible for any change in 
mortality.  In some studies, an  intervention does  target one specific prescriber  type, and  in 
this  case,  the  targeted prescriber  type may  be  entered  into  the database.  For  example,  in 
studies  where  community  case  management  interventions  have  been  used  to  decrease 
mortality  from  childhood  infections,  the  interventions  target  communities,  including 
community health worker (CHW) who live and work in these communities. Since the CHWs 
are known to be responsible for most of the patient care within such communities, they may 





Dispenser  type  refers  to  the  main  dispenser  in  the  study  irrespective  of  whether  the 
intervention is aimed at that dispenser or whether there are dispensing outcome variables. If 


















Patients  attending  primary  health‐care  facilities  are  usually  classified  as  outpatients.  (If 






separately  (in which case  two  records may be entered  into  the database),  then  the patient 
type should be ʺdonʹt knowʺ  if no particular patient type predominates by 80% or more. If 
one patient type does predominate by 80% or more, then that patient type should be used 
rather  than  ʺdonʹt  knowʺ.  In  all  cases,  a  note  should  be  made  in  section  3  of  the  % 
distribution of the patient types. 
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The  age group  chosen  should be  according  to  the upper  age  limit  allowed. For  example, 
children  less  than one year should be placed  in  the  ʺ< 1 yearʺ category and not  in  the  ʺ< 5 
yearsʺ category, even though they are clearly under 5 years as well as under 1 year. 
 
If  an  article/report  describes  drug  use  separately  for  patients  of  different  ages,  the 
study/survey should be entered into the database as one record. Such a survey should not be 
divided  into  two records merely on  the basis of patient age even  if  this means  that certain 
general drug use  indicators have  to be calculated by averaging across  results  for different 
patient ages. Some articles/reports may describe some drug use  indicators  for all ages and 
some for children < 5 years. In such articles/reports, the age group relating to the majority of 
drug use  indicators should be chosen and notes made  in sections 3 and 4 about  indicators 
relating to the age group not chosen in section 1. 







or  more  of  the  variables  ʺmalariaʺ,  ʺdiarrhoeaʺ,  ʺhypertensionʺ,  ʺAcute  respiratory  tract 
infection (ARI)ʺ,  ʺMaternal child health (MCH)ʺ,  ʺSexually  transmitted  infections (STIs)ʺ or 
“other illnesses” should be marked ʺyesʺ.  
 
ʺAll  illnessesʺ  should  be  chosen  if  drug  use  for  all  cases  are  investigated.  Even  if  ʺAll 
illnesses”  is  chosen,  one  or  more  of  the  variables  ʺmalariaʺ,  ʺdiarrhoeaʺ,  ʺhypertensionʺ, 
ʺARIʺ, ʺMCHʺ, ʺSTIsʺ or “other illnesses”  may still be marked “yes” if there is an indicator 
which is specific to a disease in the survey. For example, a general survey marked “all” may 
also be marked  “diarrhoea=yes”  if  the  indicator  “% diarrhoea  cases  treated with ORT”  is 
present. 
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Study measures specific indicators for the following diseases 
For each box  labelled    ʺmalariaʺ,  ʺdiarrhoeaʺ,  ʺhypertensionʺ,  ʺARIʺ,  ʺMCHʺ,  ʺSTIsʺ,  chose 
ʺyesʺ or ʺnoʺ 
 












For  surveys  concerning  the  integrated  management  of  childhood  illness  (IMCI),  enter 
ʺIMCIʺ  under  “other  illnesses  (describe)”  and  also  insert  ʺyesʺ  for  the  fields  ʺmalariaʺ, 













If  an  article/report  describes  drug  use  for  different  diseases,  the  study/survey  should  be 
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Data from this study can be found in the following publications 




Add or modify citation 
To enter a new citation into the database, click the cursor on the ʺAdd or modify citationʺ box. 
Once  the  box  appears,  click  on  starred  right  arrow  at  the  bottom  of  the  box.  A  new 
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Under  ʺintervention  descriptionʺ  at  the  bottom  of  section  2,  there  are  3  boxes  labelled 
ʺintervention  1ʺ,  ʺintervention  2ʺ,  ʺintervention  3ʺ.  Normally  a  description  of  the 
intervention  should  be  entered  into  one  or  more  of  these  boxes.  The  database  can 
accommodate up  to 3  intervention groups and one control group within one study/survey 





by  different  interventions  that may  be  undertaken with  each major  type  of  intervention. 
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In  some  studies,  information  is  given  about  the  extent  to  which  the  intervention  is 
implemented  e.g.  coverage. For  example,  in  IMCI  studies,  there  is  an  indicator  ʺ% health 











Large  group  provider  education  consists  of  >  15  participants  and  small  group  education 
consists of < 15 participants. 
Administrative/managerial  








therapeutic  committees)  is a  committee designated  to ensure  the  safe and effective use of 
medicines in the facility or area under its jurisdiction. 
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Community case management 
Interventions in this group involve trained members of the community providing treatment 
to members of  their own community. The subcategories  in  this group concern  the  type of 
disease  that  is  to be managed  in  the community and each box should be marked  ʺyesʺ or 
ʺnoʺ respectively.  
 
Community  case  management  usually  involves  several  interventions  which  may  be 
classified under other sections in addition to the ʺcommunity case managementʺ section. The 
relevant boxes within any section on intervention type should be marked ʺyesʺ. For example, 
community case management may  involve a package of  interventions. These may  include 
(1) training and supervision of members of the community to provide treatment for certain 
diseases,  (2)  consumer  education  on  self  treatment  and  (3)  supplying  drugs  to  a  trained 
layperson.  In  such  a  case,  interventions  under  the  sections  on  consumer  education,  
administrative/managerial  and  essential  drugs  programme/supply  may  be  marked  ʺyesʺ. 







of  systematically  developed  statements  to  help  prescribers  make  decisions  about 
appropriate treatments for specific clinical conditions. 
 






providing  health  services.  For  example,  trained  laypersons,  traditional  healers,  informal 
drug  pedlars  are  all  considered  providers,  not  consumers.  Educational  interventions 
conducted  through  the media  (e.g. TV, radio), aimed at communities  in general,  including 
informal  providers  in  the  community  (e.g.  drug  pedlars  or  traditional  healers),  are 
considered  as  consumer  education.  Only  if  the  messages  specifically  target  health‐care 
providers  in the media should such  intervention not be considered as consumer education 
only. 
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Group process strategies 
This section refers to activities where providers themselves identify a drug use problem and 
develop,  implement  and  evaluate  a  strategy  to  correct  the  problem.  Such  processes may 













This section refers  to any economic  incentive  that may  impact on drug use. The  following 
definitions apply: 
 












• A  capitation  fee  is  a  fee  paid  to  the  provider  by  the  government  or  an  insurance 
company  or  a  health  maintenance  organization  for  providing  a  specified  package  of 
health care to a patient over a specified time period. 
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• Health  insurance  is a  financing scheme characterized by risk sharing  in which regular 
payments of premiums are made by or on behalf of members  (the  insured) and where 
the  insurer  pays  the  cost  or  a  set  proportion  of  the  cost  for  covered  health  services; 
Insurance may be: 
o private health  insurance where voluntary private  indemnity  insurance  is provided 
by private insurance companies through employees, mutual societies or cooperatives  




Essential Drugs Programme/Supply 
Interventions  in  this  group  include  any  interventions  that  impacts  on  drug  supply, 
distribution  or  availability,  but  excluding  economic  incentives  such  as  pricing  or  fee 
systems. Although drug supply and distribution systems would be included in this section, 
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Type of data collected 
Choose  retrospective  or  prospective.  Interviews  or  observation  can  only  be  done 
prospectively.  
Place where data is collected 
This  refers  to where  the  data  is  collected    and  not  to whose  drug  use  is measured.  For 
example,  if  data  on  prescriptions  from  the  primary  health  facility  is  collected  during  a 
household  survey,  then  the place of data  collection  is  the household and not  the primary 
health‐care facility. Similarly  if data on treatment taken at home  is collected during exiting 
patient  interview at  the primary health‐care  facility  then  the place of data collection  is  the 
primary health‐care facility and not the household. 
Method of data collection 
This  refers  to  whether  data  is  collected  by  record  review,  observation  and/or  interview.  
Simulated  patient  surveys  are  counted  as  observation.  Patient  knowledge  can  only  be 
collected by interview. 




Total number of cases/prescriptions (all rounds) 
Total number  of  cases  or prescriptions  in  the  survey  is  calculated  as  a  total  based  on  all 
cases,  prescriptions  or  patients  in  all  groups  in  the  study  for  all  time  periods  of 
measurement.  Therefore  the  number  of  cases,  prescriptions  or  patients  for  all  groups 
(control  and  intervention  groups)  at  any  one  time  period  needs  to  be multiplied  by  the 
number  of  times  a measurement  is done.  If  the  numbers  vary  for different  outcomes,  or 
different  periods,  then  the  lowest  number  should  be  chosen.  The  same  applies  for 
catchment’s population figure for mortality rates. 




Patient  observations  or  interviews  are  usually  convenience,  not  random  samples  unless 
specifically otherwise specified. If the period of time was specifically randomly chosen and 
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In a household survey, the child suffering from a disease of interest is not randomly selected 
(although  the household s/he  lives  in may have been randomly selected  in which case  the 
other field ʺSampling point (facilities/villages) were randomly selectedʺ will be ʺyesʺ. 
Total number of health facilities 
Number  of health  facilities  in  the  survey  is based  on  the  lowest number during  any  one 
measurement or for any time period or for any outcome variable (entered into the database). 
It  is  not  calculated  by  multiplying  up  different  time  periods  as  for  total  number  of 
patients/prescriptions etc. The number of facilities does include adding up all facilities from 
both control and intervention groups at one point in time.  
Number of cases/prescriptions per facility  
Number of  cases/prescriptions per  facility  refers  to  the  lowest number  cases/prescriptions 
per facility at any one time period of measurement. If only the average number per facility is 
reported (not numbers for individual facilities) then this is reported. The number of patients/ 
prescriptions  per  health  facility  cannot  be  calculated  by  dividing  the  total  number  of 
prescriptions by the number of facilities. 








Number of households per village 
Number of households per village refers to the lowest number households per village at any 
one time period of measurement. 
Sampling point (facilities/villages) were randomly selected 





Comments about study design 
This box allows one  to comment on  the methodology and note down  inconsistencies   and 
difficulties in the methodology e.g. different sample sizes for different indicators. 
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The group refers  to which group of peopleʹs drug use  is measured.  In  the case of baseline 
studies/surveys  with  no  intervention,  the  group  would  be  ʺAllʺ.  For  intervention 




For  example,  if  section  3  mentions  a  pre‐post  study  with  control,  then  there  should  be 























For  example,  a  cross‐sectional  survey  with  no  intervention  would  only  have  ʺbaselineʺ 
entered as the period for each outcome variable. A post‐only with control study with only 
one  period  of  data  collection  would  only  have  ʺpost  1ʺ  entered  as  the  period  for  each 
outcome variable. A  time  series  study with no  control, with data  collected before, during 
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and  3  times  after  an  intervention,  would  have  for  each  outcome  variable  the  periods 



















ʺyear  of  baseline  surveyʺ  in  section  1.  For  all  intervention  studies/surveys,  the  year  of 
measure  for  the  final  period  (post  1,  2  or  3)  should  be  the  same  as  the  ʺyear  of  post 
intervention surveyʺ in section 1. 






definitions used by  the  authors  are  the  same  as  the ones used  in  the database. Particular 
attention should be paid to the numerators and denominators used in calculating indicators. 
ABs: % antibiotics prescribed in under dosage 
No. antibiotics prescribed in under-dose 
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ABs: % antibiotics prescribed inappropriately 
No. patients prescribed antibiotics 
inappropriately  








For  WHO/IMCI  studies,  the  indicator  ʺ%  antibiotics  prescribed  inappropriatelyʺ  is 
calculated by subtracting the percentage of  ʺChild not needing antibiotic  leaves the facility 
without antibioticʺ from 100%.  
ABs: % pneum. cases w. appr. antibiotics 
No. cases of pneumonia prescribed 
appropriate antibiotics 
Total no. cases of pneumonia 
x 100 
 
%  pneumonia  cases  treated  with  appropriate  antibiotics  includes  any  type  of  lower 
respiratory  tract  infection  that  the authors  say do need antibiotics. Appropriate antibiotics 









the  indicator  ʺpneumonia  cases managed  correctlyʺ  is not  the  same because all aspects of 
case  management  including  referral  and  advice  are  considered,  not  just  the  appropriate 
antibiotic. However a note of the indicator should be made in the notes box in section 4. 
 
In  WHO/IMCI  studies  the  indicator  ʺChild  with  pneumonia  is  correctly  treatedʺ  is 
interpreted  as  ʺ%  pneum.  cases  w.  appr.  Antibioticsʺ  because  this  indicator  does  not 
generally include other aspects of case management (such as dosing, referral and advice). 
ABs: % cases of URTI treated with antibiotics 
No. cases upper respiratory tract infection 
prescribed antibiotics 
Total no. cases of upper respiratory tract 
infection 
x 100 
  Annex 3: indicators database manual 
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% of upper respiratory tract  infections (URTI) treated with antibiotics  includes any type of 
upper  respiratory  tract  infection  that  the  authors  say  do  not  need  antibiotics.  In  some 
studies/surveys,  the  authors  may  state  that  viral  URTI  (e.g.  common  cold,  sore  throat) 
should be  treated with antibiotics. For such studies  the  indicator  ʺ% cases of URTI  treated 







the  indicator  ʺARI  cases  who  should  not  receive  antibiotics  but  were  given  themʺ  is 
interpreted as ʺ% cases of URTI treated with antibioticsʺ. 
ABs: % patients prescribed antibiotics 
No. patient encounters where one or more 
antibiotics are prescribed 




not defined  as  an  antibiotic;    if  the  authors define metronidazole  as  an  antibiotic,  a  note 
should be made in section 4. 
ARI: % ARI cases treated with cough syrups 
No. cases acute respiratory tract infection 
prescribed cough syrups 
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Avail: % facilities with spec. drug avail 
No. facilities with a specific drug available 









Cost: % drug costs on antibiotics 
Cost for all antibiotics 




the survey.  If  the year of survey  is unknown,  the year of publication may be used, a note 
being made in the notes box of section 4. 
Cost: % drug costs on injections 
Cost for all injections 




the survey.  If  the year of survey  is unknown,  the year of publication may be used, a note 
being made in the notes box of section 4. 
Cost: Av. drug cost per patient (USD) 
Cost for all drugs prescribed 






Diarrhoea: % treated with ORT 
No. cases of diarrhoea treated with oral 
rehydration therapy 
Total no. cases of diarrhoea 
x 100 
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In  WHO,  Division  of  Child  Health  and  Development  (WHO/CHD)  control  of  diarrhoea 
studies, the indicator ʺCorrectly rehydratedʺ  is not  interpreted as % diarrhoea treated with 
ORT  because  all  aspects  of  rehydration  are  included  not  just  prescription  of  Oral 









Diarrhoea: % treated with anti-diarrhoeals 
No. cases of diarrhoea treated with anti-
diarrhoeals 
Total no. cases of diarrhoea 
x 100 
 
Anti‐diarrhoeal drugs are medicines defined by  the authors as  relieving  the  symptoms of 
diarrhoea. They are non‐antibiotic drugs and  include adsorbents and bulk  forming drugs, 
anti‐motility  drugs  and  anti‐spasmodic  drugs.  Often  such  preparations  are  fixed  dose 
combination products. 
Diarrhoea: % treated w. antibiotics 
No. cases of diarrhoea treated with antibiotics 
Total no. cases of diarrhoea 
x 100 
 
Anti‐amoebic  drugs  such  as  metronidazole  are  often  inappropriately  used  to  treat  acute 
diarrhoea. They  should  not  be  classed  as  an  antibiotic  in  the database.  If  a  study/survey 
reports use of anti‐amoebic drugs to treat diarrhoea, a note should be made  in section 4 of 
the % of diarrhoea cases treated with metronidazole (or anti‐amoebic drug). 
Drugs: Av. no drugs per patient 
Total no. of different drug products prescribed 
No. of patient encounters observed 
 
Drugs: % patients treated without drugs 
No. patient consultations in which drugs are 
not prescribed 
Total no. of patient consultations surveyed 
x 100 
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Drugs: % key drugs available in facility 
No. specified drug products actually in stock 
Total no. of drug products on a pre-
determined list of key drugs 
x 100 
 
For WHO/IMCI studies,  the  indicator  ʺIndex of availability of essential oral  treatmentsʺ  is 
interpreted as the indicator ʺ% key drugs available in the facilityʺ. 
Drugs: % prescribed that are dispensed 
No. drugs actually dispensed at the health 
facility 
Total no. drugs prescribed 
x 100 
EDL: % prescribed drugs from EML (EDL) 
No. drug products prescribed which are listed 
on the EML 
Total no. drug products prescribed 
x 100 
EDL: % facilities with EML (EDL) available 
No. facilities with national EML or local 
formulary available in facility 
Total no. of facilities 
x 100% 
Generic: % prescribed by generic name 
No. drugs prescribed by generic name 
Total no. drugs prescribed 
x 100 
Info: % patients given dosage instructions 
No. of patients given dosage instructions 
Total no. of patients observed 
x 100 
 






In WHO/CHD  control  of ARI  studies  ʺ%  caretakers given dosage  instructionsʺ  should be 
interpreted from the text with regard to % caretakers given dosing instructions with regard 
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For WHO/IMCI  studies,  the  indicator  ʺChild  prescribed  oral medication whose  caretaker 
received counselling on how to administer the treatmentʺ is interpreted as the indicator ʺ% 
patients given dosage instructionsʺ. 
Info: % facilities with impartial information 
No. facilities where a listed source of impartial 
information is present 
Total no. of facilities surveyed 
x 100 
Inject: % patients prescribed injections 
No. patient encounters where one or more 
injections are prescribed 
Total no. patient encounters surveyed 
x 100 
Inject: % patients prescribed injections inappropriately 
No. patients prescribed injections 
inappropriately 





Know: % patients with correct dosage knowledge 
No. patients adequately reporting dosage 
schedule for all drugs 
Total no. patients interviewed 
x 100 
 
In  WHO/CHD  diarrhoea  control  studies,  patient  knowledge  about  the  preparation  and 
administration of oral  rehydration solution  (ORS)  is used  for  interpreting  the  indicator on 
ʺ% patients with correct dosage knowledgeʺ because this is the nearest equivalent to dosing 
information.  Sometimes  this  overall  indicator  is  not  given  and  only  the  individual 
components are given consisting of ORS preparation, how much and when to give, and how 
long to keep when prepared. In these circumstances the result for ʺwhen and how much to 
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In WHO/CHD ARI control studies, patient knowledge should be  interpreted  from  the  text 




and/or antimalarial can describe how  to give  treatmentʺ  is  interpreted as  the  indicator  ʺ% 
patients with correct dosage knowledgeʺ. 
Label: % drugs adequately labelled 
No. of drug packages adequately labelled 
Total no. drug packages dispensed 
x 100 
 
Adequate  labelling  should be defined by  the authors. An adequate  label  should normally 
include at least patient name, drug name and when the drug should be taken. If the authors 
definition differs from this, a note should be made in section 4. 
Malaria: % treated w appr.anti-malarials 
No. cases of malaria prescribed appropriate 
anti-malarial 
Total no. cases of pneumonia 
x 100 
 







ʺ Malaria: %  treated w  appr.anti‐malarialsʺ  because  this  indicator does  not  include  other 
aspects of case management. 
Mortality rates 
No. deaths over a defined period of time in a 
defined population 




Mortality  rates  are  usually  expressed  as  no.  deaths  per  1000  persons  at  risk  and  can  be 
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The  age group of  the population  at  risk  and  the  size of  the population  at  risk  should be 
entered  in  the  relevant  boxes  ʺAge  groupʺ  and  ʺTotal  populationʺ  in  section  3  under  ʺIf 
mortality studyʺ. 
Pregnant: % treated with iron +/- folic acid 
No. pregnant women treated with iron +/- 
folic acid 





POM: % patients receiving without prescription 
No. patients that receive a POM without a 
prescription  







Satis: % patients satisfied with treatment  
No. of patients who report being generally 
satisfied 





STG: % treated in accordance with STGs 
No. cases treated in accordance with standard 
treatment guidelines 
Total no. of cases reviewed 
x 100 
 
Treatment  in accordance with Standard Treatment Guidelines  is as  judged by  the authors. 
This  STG  adherence  indicator  normally  concerns drug  treatment  only.  If  it  concerns  also 
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patient  assessment,  referral  and  caretaker  advice  as  in ARI/CDD/IMCI  studies,  then  this 
should be indicated in the notes box in section 4. 
 
For WHO/CHD ARI control studies,  the STG  indicator concerns  treatment  for all  types of 
ARI and not just pneumonia.  
 
For  WHO/CHD  diarrhoea  control  studies,  the  STG  indicator  concerns  the  correct 
rehydration for diarrhoea cases (both ORS, IVI, dose, duration, etc.) and does not refer to the 
%  of  diarrhoea  or  dysentery  cases  treated  with  antibiotics  or  ORS  for  which  there  are 
separate  indicators.  It does not  refer  to  the % of  children  correctly managed because  that 
indicator includes correct assessment, advice and referral. 
 
For WHO/IMCI studies,  the  indicator  ʺChild needing oral antibiotic and/or antimalarial  is 
prescribed drug(s)  correctlyʺ  is  interpreted as  the  indicator  ʺ%  treated  in accordance with 
STGsʺ. It does not refer to the % of children correctly managed because that includes correct 
assessment, advice and referral. 
STG: % facilities with STGs available 
No. facilities with national STG or local 
protocols available in facility 




as  STGs.  If  not  all  these  three  are  present,  the  minimum  that  must  be  present  for 
interpretation as STG availability is the booklet. 
Time: Av. consultation time (min.) 
Total time for a series of patient consultations 




Time: Av. dispensing time (sec.) 
Total time for dispensing drugs to a series of 
patients 
Number of patient encounters 
 
 
Dispensing  includes preparation of a prescription and  interaction between  the patient and 
the  dispenser.  Dispensing  time  may  include  or  exclude  prescription  preparation  time. 
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Vits: % cases prescribed multivit/tonics 
No. patient encounters where 1 or more 
vitamins/tonics are prescribed 











note  should  be  made  of  exactly  what  was  done  in  the  box  ʺnotes  on  study  outcome 
measuresʺ at the bottom of section 4. In all cases, averaging should be done at the level of the 
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Calculating  indicators where  the  indicator  is  not  given  and where  only  some  data  on 

































                  = (90 + 225 + 120)/60 = 444/60 = 7.4 mins 
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